CUMULATIVE SUPPLEMENT 4
APRIL 2005



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2005

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

Cumulative Supplement 4

April 2005

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

CUMULATIVE SUPPLEMENT 4
April 2005

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS	UCB PHARMA INC (UCB)
FUJISAWA HEALTHCARE	ASTELLAS PHARMA US INC

(FUJISAWA HLTHCARE)	(ASTELLAS)
SHIRE LABORATORIES INC	SHIRE DEVELOPMENT INC
(SHIRE LABS)	(SHIRE)
SHIRE PHARMACEUTICAL DEVELOPMENT INC	SHIRE DEVELOPMENT INC
(SHIRE PHARM)	(SHIRE)
YAMANOUCHI PHARMA AMERICA INC	ASTELLAS PHARMA US INC
(YAMANOUCHI)	(ASTELLAS)

1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at http://www.fda.gov/cder/ob/default.htm. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and

effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2004	MAR 2005	JUN 2005	SEP 2005
DRUG PRODUCTS LISTED	11082	11184		
SINGLE SOURCE	2427 (21.9%)	2437 (21.8%)		
MULTISOURCE	8547 (77.1%)	8637 (77.2%)		
THERAPEUTICALLY EQUIVALENT	8327 (75.1%)	8428 (75.4%)		
NOT THERAPEUTICALLY EQUIVALENT	220 (2.0%)	209 (1.9%)		
EXCEPTIONS[1]	108 (1.0%)	110 (1.0%)		
NEW MOLECULAR ENTITIES APPROVED	9	2		
NUMBER OF APPLICANTS	625	631		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, APAP, AND CAFFEINE

AB		WATSON LABS	325MG;50MG;40MG	N89536	001	Feb 16, 1988	Feb	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND TRAMADOL HCL

AB		KALI LABS	325MG;37.5MG	N76475	001	Apr 21, 2005	Mar	NEWA

ULTRACET

AB	+	ORTHO MCNEIL PHARM	325MG;37.5MG	N21123	001	Aug 15, 2001	Mar	CFTG

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

AT	+	MORTON GROVE	2%	N40166	001	Jul 26, 1996	Jan	CRLD
AT		VINTAGE	2%	N40607	001	Feb 24, 2005	Feb	NEWA

VOSOL

	@	MEDPOINTE PHARM HLC	2%	N12179	001		Jan	DISC

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

	+	UCB	8MG;60MG	N19806	001	Mar 25, 1994	Mar	CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB		TEVA PHARMS	200MG	N74914	001	Nov 26, 1997	Mar	CAHN

TABLET; ORAL

ACYCLOVIR

AB		TEVA PHARMS	400MG	N75021	001	Mar 18, 1998	Mar	CAHN
AB			800MG	N75021	002	Mar 18, 1998	Mar	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

	@	ABBOTT	EQ 50MG BASE/ML	N75114	001	Jul 26, 1999	Feb	DISC

ADENOSINE

INJECTABLE; INJECTION

ADENSOINE

>A>	AP	AM PHARM	3MG/ML	N77133	001	Apr 27, 2005	Apr	NEWA

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	+	DEY	EQ 0.083% BASE	N72652	001	Feb 21, 1992	Jan	CRLD

TABLET; ORAL

ALBUTEROL SULFATE

>A>	AB	+ MYLAN	EQ 2MG BASE	N72894	002	Jan 17, 1991	Apr	CMS1

ALENDRONATE SODIUM

SOLUTION; ORAL
FOSAMAX

>D>		+	MERCK	EQ 70MG ACID/75ML	N21575	001	Sep 17, 2003	Apr CPOT
>A>		+		EQ 70MG BASE/75ML	N21575	001	Sep 17, 2003	Apr CPOT

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL
FOSAMAX PLUS D

>A>		+	MERCK	EQ 70MG BASE;2,800 IU	N21762	001	Apr 07, 2005	Apr NEWA

ALPRAZOLAM

TABLET, ORALLY DISINTEGRATING; ORAL
NIRAVAM

			SCHWARZ PHARMA	0.25MG	N21726	001	Jan 19, 2005	Jan NEWA
				0.5MG	N21726	002	Jan 19, 2005	Jan NEWA
				1MG	N21726	003	Jan 19, 2005	Jan NEWA
		+		2MG	N21726	004	Jan 19, 2005	Jan NEWA

ALPROSTADIL

INJECTABLE; INJECTION
EDEX

>D>		+	SCHWARZ PHARMA	0.01MG/VIAL	N20649	005	Jul 30, 1998	Apr CTEC
>A>	AP	+		0.01MG/VIAL	N20649	005	Jul 30, 1998	Apr CTEC
>D>		+		0.02MG/VIAL	N20649	006	Jul 30, 1998	Apr CTEC
>A>	AP	+		0.02MG/VIAL	N20649	006	Jul 30, 1998	Apr CTEC
>D>		+		0.04MG/VIAL	N20649	007	Jul 30, 1998	Apr CTEC
>A>	AP	+		0.04MG/VIAL	N20649	007	Jul 30, 1998	Apr CTEC

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL

	AA		TEVA PHARMS	50MG/5ML	N73115	001	Aug 23, 1991	Mar CAHN

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN 7%

			HOSPIRA	7% (7GM/100ML)	N17673	002		Mar CMFD

AMINOSYN 8.5%

			HOSPIRA	8.5% (8.5GM/100ML)	N17673	004		Mar CMFD

AMIODARONE

INJECTABLE; INTRAVENOUS
AMIODARONE HCL

	AP		APOTEX	50MG/ML	N77161	001	Apr 20, 2005	Mar NEWA

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HCL

	AP	+	AM PHARM PARTNERS	50MG/ML	N75761	001	Oct 15, 2002	Mar CRLD
	AP	+	APOTEX	50MG/ML	N76394	001	Apr 25, 2003	Mar CRLD
	AP	+	BEDFORD	50MG/ML	N76018	001	Oct 15, 2002	Mar CRLD
	AP	+	BEDFORD LABS	50MG/ML	N76299	001	Oct 24, 2002	Mar CRLD
	AP	+	BEN VENUE	50MG/ML	N76088	001	Oct 15, 2002	Mar CRLD
	AP	+	BIONICHE (CANADA)	50MG/ML	N76217	001	Oct 15, 2002	Mar CRLD

		INJECTABLE; INJECTION						
		AMIODARONE HCL						
AP	+	MAYNE PHARMA USA	50MG/ML	N76108	001	Oct 15, 2002	Mar	CRLD
AP	+	SICOR PHARMS	50MG/ML	N76163	001	Sep 05, 2003	Mar	CRLD
		TABLET; ORAL						
		AMIODARONE HCL						
AB		AUROSAL PHARMS	200MG	N77069	001	Apr 08, 2005	Mar	NEWA
AB			400MG	N77069	002	Apr 08, 2005	Mar	NEWA
AB		TARO	100MG	N75424	002	Dec 18, 2002	Mar	CTEC
AB		TEVA PHARMS	200MG	N74739	001	Nov 30, 1998	Mar	CAHN
		PACERONE						
AB		UPSHER SMITH	100MG	N75135	002	Apr 12, 2005	Mar	NEWA
		AMOXICILLIN						
		FOR SUSPENSION; ORAL						
		TRIMOX						
>D>		@ APOTHECON	50MG/ML	N61886	001		Apr	CMFD
>A>	AB		50MG/ML	N61886	001		Apr	CMFD
>D>		@	125MG/5ML	N61886	002		Apr	CMFD
>A>	AB		125MG/5ML	N61886	002		Apr	CMFD
>D>		@	250MG/5ML	N61886	003		Apr	CMFD
>A>	AB		250MG/5ML	N61886	003		Apr	CMFD
		AMOXICILLIN; CLAVULANATE POTASSIUM						
		FOR SUSPENSION; ORAL						
		AMOXICILLIN AND CLAVULANATE POTASSIUM						
AB		HIKMA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	N65191	002	Jan 25, 2005	Jan	NEWA
AB			400MG/5ML;EQ 57MG BASE/5ML	N65191	001	Jan 25, 2005	Jan	NEWA
		TABLET, CHEWABLE; ORAL						
		AMOXICILLIN AND CLAVULANATE POTASSIUM						
AB		TEVA	200MG;EQ 28.5MG BASE	N65205	001	Feb 09, 2005	Jan	NEWA
AB			400MG;EQ 57MG BASE	N65205	002	Feb 09, 2005	Jan	NEWA
		AMPICILLIN SODIUM						
		INJECTABLE; INJECTION						
		AMPICILLIN SODIUM						
AP		INSTITUTO BIOCHEMICO	EQ 125MG BASE/VIAL	N62797	001	Jul 12, 1993	Jan	CMFD
AP			EQ 2GM BASE/VIAL	N62797	002	Jul 12, 1993	Jan	CAHN
		ANAGRELIDE HYDROCHLORIDE						
		CAPSULE; ORAL						
		AGRYLIN						
AB		SHIRE	EQ 0.5MG BASE	N20333	001	Mar 14, 1997	Mar	CFTG
AB	+		EQ 1MG BASE	N20333	002	Mar 14, 1997	Mar	CFTG
		ANAGRELIDE HCL						
AB		BARR	EQ 0.5MG BASE	N76530	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76530	002	Apr 18, 2005	Mar	NEWA
AB		EON	EQ 0.5MG BASE	N76683	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76683	002	Apr 18, 2005	Mar	NEWA
AB		IMPAX LABS	EQ 0.5MG BASE	N76910	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76910	002	Apr 18, 2005	Mar	NEWA
AB		IVAX PHARMS	EQ 0.5MG BASE	N76468	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76468	002	Apr 18, 2005	Mar	NEWA
AB		MYLAN	EQ 0.5MG BASE	N76811	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76811	002	Apr 18, 2005	Mar	NEWA
AB		ROXANE	EQ 0.5MG BASE	N76489	001	Apr 18, 2005	Mar	NEWA

CAPSULE; ORAL
ANAGRELIDE HCL

AB	ROXANE	EQ 1MG BASE	N76489	002	Apr 18, 2005	Mar		NEWA
AB	WATSON LABS	EQ 0.5MG BASE	N76417	001	Apr 18, 2005	Mar		NEWA
AB		EQ 1MG BASE	N76417	002	Apr 18, 2005	Mar		NEWA

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	MYLAN	25MG	N73457	002	Apr 26, 1999	Mar		CTEC
AB	TEVA PHARMS	50MG	N74120	001	Feb 24, 1995	Mar		CAHN
AB		100MG	N74120	002	Feb 24, 1995	Mar		CAHN
AB	ZYDUS PHARMS USA	25MG	N76900	001	Jan 28, 2005	Jan		NEWA
AB		50MG	N76900	002	Jan 28, 2005	Jan		NEWA
AB		100MG	N76900	003	Jan 28, 2005	Jan		NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL
STRATTERA

	LILLY	80MG	N21411	007	Feb 14, 2005	Feb		NEWA
		100MG	N21411	008	Feb 14, 2005	Feb		NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

>D>	VANCERIL							
>D>	+ SCHERING	0.042MG/INH	N17573	001			Apr	DISC
>A>	@	0.042MG/INH	N17573	001			Apr	DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

	@ HOLLISTER STIER LABS	60UMOLAR	N50114	001			Mar	DISC

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	TEVA PHARMS	EQ 0.05% BASE	N71882	001	Jun 06, 1988	Mar		CAHN

OINTMENT; TOPICAL
ALPHATREX

	@ SAVAGE LABS	EQ 0.05% BASE	N19143	001	Sep 04, 1984	Jan		DISC

BETAMETHASONE VALERATE

LOTION; TOPICAL
BETAMETHASONE VALERATE

AB	TEVA PHARMS	EQ 0.1% BASE	N71883	001	Apr 22, 1988	Mar		CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL
DUVOID

>D>	@ WELLSPRING PHARM	50MG	N85882	003			Apr	CMFD
>A>	AA	50MG	N85882	003			Apr	CMFD

BISOPROLOL FUMARATE

TABLET; ORAL
BISOPROLOL FUMARATE

AB	TEVA PHARMS	5MG	N75644	001	Jun 26, 2001	Mar		CAHN

TABLET; ORAL
BISOPROLOL FUMARATE

AB		TEVA PHARMS	10MG	N75644	002	Jun 26, 2001	Mar	CAHN

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
XIBROM

	+	ISTA PHARMS	0.09%	N21664	001	Mar 24, 2005	Mar	NEWA

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL
BROMOCRIPTINE MESYLATE

AB		MYLAN	EQ 5MG BASE	N77226	001	Apr 04, 2005	Mar	NEWA

PARLODEL

AB	+	NOVARTIS	EQ 5MG BASE	N17962	002	Mar 01, 1982	Mar	CTEC

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPRENORPHINE HCL

AP		BEDFORD	EQ 0.3MG BASE/ML	N76931	001	Mar 02, 2005	Feb	NEWA

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL
MENTAX

>D>	+	BERTEK PHARMS	1%	N20524	001	Oct 18, 1996	Apr	CAHN
>A>	+	MYLAN BERTEK	1%	N20524	001	Oct 18, 1996	Apr	CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT

BR		G AND W LABS	100MG;2MG	N86557	001	Oct 04, 1983	Feb	CMFD

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB		TEVA PHARMS	12.5MG	N74462	001	Feb 13, 1996	Mar	CAHN
AB			25MG	N74462	002	Feb 13, 1996	Mar	CAHN
AB			50MG	N74462	003	Feb 13, 1996	Mar	CAHN
AB			100MG	N74462	004	Feb 13, 1996	Mar	CAHN

CARBAMAZEPINE

SUSPENSION; ORAL
CARBAMAZEPINE

	@	TARO	100MG/5ML	N75875	001	Dec 21, 2000	Mar	DISC

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN

AP		EON	50MG/VIAL	N76959	001	Mar 18, 2005	Mar	NEWA
AP			150MG/VIAL	N76959	002	Mar 18, 2005	Mar	NEWA
AP			450MG/VIAL	N76959	003	Mar 18, 2005	Mar	NEWA

CEFACLOR

CAPSULE; ORAL
CECLOR

	@	LILLY	EQ 250MG BASE	N50521	001		Mar	DISC

		CAPSULE; ORAL							
		CECLOR							
		@ LILLY	EQ 500MG BASE	N50521	002		Mar	DISC	
		CEFACLOR							
	AB	+ RANBAXY	EQ 500MG BASE	N64156	002	Aug 28, 1997	Mar	CRLD	
		FOR SUSPENSION; ORAL							
>D>		CECLOR							
>D>	AB	CEPH INTL	EQ 125MG BASE/5ML	N62206	001		Apr	CTNA	
>D>	AB		EQ 187MG BASE/5ML	N62206	003	Apr 20, 1988	Apr	CTNA	
>D>	AB		EQ 250MG BASE/5ML	N62206	002		Apr	CTNA	
>D>	AB		EQ 375MG BASE/5ML	N62206	004	Apr 20, 1988	Apr	CTNA	
	AB		EQ 375MG BASE/5ML	N62206	004	Apr 20, 1988	Mar	CRLD	
		@ LILLY	EQ 125MG BASE/5ML	N50522	001		Mar	DISC	
		@	EQ 250MG BASE/5ML	N50522	002		Mar	DISC	
>A>		CEFACLOR							
>A>	AB	CEPH INTL	EQ 125MG BASE/5ML	N62206	001		Apr	CTNA	
>A>	AB		EQ 187MG BASE/5ML	N62206	003	Apr 20, 1988	Apr	CTNA	
>A>	AB		EQ 250MG BASE/5ML	N62206	002		Apr	CTNA	
>A>	AB		EQ 375MG BASE/5ML	N62206	004	Apr 20, 1988	Apr	CTNA	
	AB	+ RANBAXY	EQ 375MG BASE/5ML	N64155	001	Oct 02, 1997	Mar	CRLD	
		CEFADROXIL/CEFADROXIL HEMIHYDRATE							
		TABLET; ORAL							
		CEFADROXIL							
>D>		@ IVAX PHARMS	EQ 1GM BASE	N62774	001	Apr 08, 1987	Apr	CMFD	
>A>	AB		EQ 1GM BASE	N62774	001	Apr 08, 1987	Apr	CMFD	
		CEFAZOLIN SODIUM							
		INJECTABLE; INJECTION							
		CEFAZOLIN SODIUM							
	AP	+ AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N64169	001	Aug 14, 1998	Mar	CRLD	
	AP	+	EQ 1GM BASE/VIAL	N64169	002	Aug 14, 1998	Mar	CRLD	
	AP	+	EQ 10GM BASE/VIAL	N64170	001	Mar 18, 1998	Mar	CRLD	
>A>	AP	ORCHID HLTHCARE	EQ 500MG BASE/VIAL	N65226	001	Apr 21, 2005	Apr	NEWA	
>A>	AP		EQ 1GM BASE/VIAL	N65226	002	Apr 21, 2005	Apr	NEWA	
		CEFTRIAXONE SODIUM							
		INJECTABLE; IM-IV							
		CEFTRIAXONE							
>A>	AP	SANDOZ	EQ 250MG BASE/VIAL	N65169	001	May 09, 2005	Apr	NEWA	
>A>	AP		EQ 500MG BASE/VIAL	N65169	002	May 09, 2005	Apr	NEWA	
>A>	AP		EQ 1GM BASE/VIAL	N65169	003	May 09, 2005	Apr	NEWA	
>A>	AP		EQ 2GM BASE/VIAL	N65169	004	May 09, 2005	Apr	NEWA	
		INJECTABLE; INJECTION							
>A>		CEFTRIAXONE							
>A>	AP	SANDOZ	EQ 1GM BASE/VIAL	N65204	001	May 03, 2005	Apr	NEWA	
>A>	AP		EQ 2GM BASE/VIAL	N65204	002	May 03, 2005	Apr	NEWA	
>A>	AP		EQ 10GM BASE/VIAL	N65168	001	May 17, 2005	Apr	NEWA	
>A>		CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER							
>A>	AP	+ B BRAUN	EQ 1GM BASE/VIAL	N50796	001	Apr 20, 2005	Apr	NEWA	
>A>	AP	+	EQ 2GM BASE/VIAL	N50796	002	Apr 20, 2005	Apr	NEWA	
		ROCEPHIN							
>D>		HLR	EQ 250MG BASE/VIAL	N63239	001	Aug 13, 1993	Apr	DISC	
>A>		@	EQ 250MG BASE/VIAL	N63239	001	Aug 13, 1993	Apr	DISC	
>D>			EQ 500MG BASE/VIAL	N63239	002	Aug 13, 1993	Apr	DISC	
>A>		@	EQ 500MG BASE/VIAL	N63239	002	Aug 13, 1993	Apr	DISC	
>D>		+	EQ 1GM BASE/VIAL	N62654	002	Apr 30, 1987	Apr	CFTG	

INJECTABLE; INJECTION

ROCEPHIN

>A>	AP	+	HLR	EQ 1GM BASE/VIAL	N62654	002	Apr 30, 1987	Apr	CFTG
		+		EQ 1GM BASE/VIAL	N62654	002	Apr 30, 1987	Mar	CRLD
>D>				EQ 1GM BASE/VIAL	N63239	003	Aug 13, 1993	Apr	DISC
>A>			@	EQ 1GM BASE/VIAL	N63239	003	Aug 13, 1993	Apr	DISC
>D>				EQ 2GM BASE/VIAL	N62654	003	Apr 30, 1987	Apr	CFTG
>A>	AP	+		EQ 2GM BASE/VIAL	N62654	003	Apr 30, 1987	Apr	CFTG
>D>		+		EQ 10GM BASE/VIAL	N50585	005	Dec 21, 1984	Apr	CFTG
>A>	AP	+		EQ 10GM BASE/VIAL	N50585	005	Dec 21, 1984	Apr	CFTG

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

>D>		+	B BRAUN	EQ 15MG BASE/ML	N50780	001	Feb 21, 2001	Apr	CPOT
>A>	AP	+		EQ 750MG BASE/VIAL	N50780	001	Feb 21, 2001	Apr	CPOT
>D>		+		EQ 30MG BASE/ML	N50780	002	Feb 21, 2001	Apr	CPOT
>A>	AP	+		EQ 1.5GM BASE/VIAL	N50780	002	Feb 21, 2001	Apr	CPOT

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

			@ APOTHECON	EQ 250MG BASE	N63186	001	Dec 30, 1994	Mar	DISC
			@	EQ 500MG BASE	N63186	002	Dec 30, 1994	Mar	DISC
	AB		BELCHER	EQ 250MG BASE	N62713	001	Jul 15, 1988	Jan	CAHN
	AB			EQ 500MG BASE	N62713	002	Jul 15, 1988	Jan	CAHN
	AB		SUN PHARM INDS (IN)	EQ 250MG BASE	N62791	001	Jun 11, 1987	Jan	CAHN
	AB			EQ 500MG BASE	N62791	002	Jun 11, 1987	Jan	CAHN
	AB		YUNG SHIN PHARM	EQ 250MG BASE	N65152	001	Feb 24, 2005	Feb	NEWA
	AB			EQ 500MG BASE	N65152	002	Feb 24, 2005	Feb	NEWA

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

		+	UCB	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369	001	Jun 21, 2004	Mar	CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUSSIONEX

		+	UCB	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	N19111	001	Dec 31, 1987	Mar	CAHN

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HCL

>D>	BP		SANDOZ	10MG	N80439	001		Apr	CRLD
>A>	BP	+		10MG	N80439	001		Apr	CRLD
>D>	BP			100MG	N80439	004		Apr	CRLD
>A>	BP	+		100MG	N80439	004		Apr	CRLD

>D> THORAZINE

>D>	BP	+	GLAXOSMITHKLINE	10MG	N09149	002		Apr	DISC
>A>			@	10MG	N09149	002		Apr	DISC
>D>	BP			25MG	N09149	007		Apr	DISC
>A>			@	25MG	N09149	007		Apr	DISC
>D>	BP			50MG	N09149	013		Apr	DISC
>A>			@	50MG	N09149	013		Apr	DISC

		TABLET; ORAL							
>D>		THORAZINE							
>D>	BP	+ GLAXOSMITHKLINE	100MG	N09149	018			Apr	DISC
>A>		@	100MG	N09149	018			Apr	DISC
>D>	BP		200MG	N09149	020			Apr	DISC
>A>		@	200MG	N09149	020			Apr	DISC
		CHOLESTYRAMINE							
		POWDER; ORAL							
		CHOLESTYRAMINE							
	AB	TEVA PHARMS	EQ 4GM RESIN/PACKET	N74554	001	Oct 02, 1996		Mar	CAHN
	AB		EQ 4GM RESIN/SCOOPFUL	N74554	002	Oct 02, 1996		Mar	CAHN
		CHOLESTYRAMINE LIGHT							
	AB	TEVA PHARMS	EQ 4GM RESIN/PACKET	N74555	001	Sep 30, 1998		Mar	CAHN
	AB		EQ 4GM RESIN/SCOOPFUL	N74555	002	Sep 30, 1998		Mar	CAHN
		CICLOPIROX							
		CREAM; TOPICAL							
		CICLOPIROX							
	AB	TARO	0.77%	N76790	001	Apr 12, 2005		Mar	NEWA
		CILOSTAZOL							
		TABLET; ORAL							
		CILOSTAZOL							
	AB	COREPHARMA	50MG	N77150	001	Mar 11, 2005		Feb	NEWA
	AB	IVAX PHARMS	100MG	N77020	002	Mar 01, 2005		Feb	NEWA
>A>	AB	ROXANE	50MG	N77024	001	May 17, 2005		Apr	NEWA
>A>	AB		100MG	N77024	002	May 17, 2005		Apr	NEWA
		CIMETIDINE HYDROCHLORIDE							
		SOLUTION; ORAL							
		CIMETIDINE HCL							
	AA	TEVA PHARMS	EQ 300MG BASE/5ML	N74859	001	Jul 09, 1998		Mar	CAHN
		CIPROFLOXACIN HYDROCHLORIDE							
		SOLUTION/DROPS; OPHTHALMIC							
		CIPROFLOXACIN							
	AT	HITECH PHARMA	EQ 0.3% BASE	N76673	001	Jan 21, 2005		Jan	NEWA
		TABLET; ORAL							
		CIPROFLOXACIN							
	AB	COBALT	EQ 100MG BASE	N76794	001	Feb 10, 2005		Jan	NEWA
	AB	SANDOZ	EQ 100MG BASE	N75939	001	Mar 03, 2005		Feb	NEWA
	AB	TARO	EQ 100MG BASE	N76912	001	Feb 18, 2005		Jan	NEWA
		CITALOPRAM HYDROBROMIDE							
		TABLET; ORAL							
		CITALOPRAM HYDROBROMIDE							
>A>	AB	AKYMA PHARMS	EQ 10MG BASE	N77045	003	Apr 29, 2005		Apr	NEWA
>A>	AB		EQ 20MG BASE	N77045	002	Apr 29, 2005		Apr	NEWA
>A>	AB		EQ 40MG BASE	N77045	001	Apr 29, 2005		Apr	NEWA
	AB	MYLAN	EQ 10MG BASE	N77039	001	Feb 03, 2005		Jan	NEWA
	AB		EQ 20MG BASE	N77039	002	Feb 03, 2005		Jan	NEWA
	AB		EQ 40MG BASE	N77039	003	Feb 03, 2005		Jan	NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

		RANBAXY	1GM	N65210	001	Jan 26, 2005	Jan	NEWA
>A>	AB	TEVA	500MG	N65154	001	May 18, 2005	Apr	NEWA

TABLET; ORAL

CLARITHROMYCIN

	AB	GENPHARM	250MG	N65195	001	Mar 11, 2005	Feb	NEWA
	AB		500MG	N65195	002	Mar 11, 2005	Feb	NEWA

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

	AA	TEVA PHARMS	EQ 0.5MG BASE/5ML	N73095	001	Apr 21, 1992	Mar	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

	AB	ZYDUS PHARMS USA	EQ 75MG BASE	N65217	001	Jan 31, 2005	Jan	NEWA
	AB		EQ 150MG BASE	N65217	002	Jan 31, 2005	Jan	NEWA
	AB		EQ 300MG BASE	N65217	003	Jan 31, 2005	Jan	NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

	AP	HOSPIRA	EQ 150MG BASE/ML	N62943	001	Sep 29, 1988	Mar	CMFD

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

	AB1	TEVA PHARMS	0.05%	N74087	001	Feb 16, 1994	Mar	CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

	AB	TEVA PHARMS	0.05%	N74089	001	Feb 16, 1994	Mar	CAHN

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

>A>	AB	KALI LABS	0.5MG	N77147	001	May 02, 2005	Apr	NEWA
>A>	AB		1MG	N77147	002	May 02, 2005	Apr	NEWA
>A>	AB		2MG	N77147	003	May 02, 2005	Apr	NEWA

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

	+	TARO	1%	N72640	001	Aug 31, 1993	Feb	CRLD

LOTRIMIN

		@ SCHERING PLOUGH	1%	N17619	001		Feb	DISC

MYCELEX

		@ BAYER PHARMS	1%	N18183	001		Feb	DISC

CLOZAPINE

TABLET; ORAL

CLOZAPINE

>A>		IVAX PHARMS	50MG	N74949	004	Apr 25, 2005	Apr	NEWA

TABLET; ORAL
CLOZAPINE

>A>	AB	TEVA	25MG	N75162	001	Apr 26, 2005	Apr	NEWA
>A>	AB		100MG	N75162	002	Apr 26, 2005	Apr	NEWA

CROMOLYN SODIUM

SOLUTION, CONCENTRATE; ORAL
GASTROCROM

	+	UCB	100MG/5ML	N20479	001	Feb 29, 1996	Mar	CAHN

CYANOCOBALAMIN

SPRAY, METERED; NASAL
NASCOBAL

	+	NASTECH PHARM	0.5MG/SPRAY	N21642	001	Jan 31, 2005	Jan	NEWA
	+	QUESTCOR PHARMS	0.5MG/SPRAY	N21642	001	Jan 31, 2005	Feb	CAHN

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE

	AB1	IVAX PHARMS	25MG	N65110	003	Mar 29, 2005	Mar	NEWA
	AB1		50MG	N65110	001	Mar 29, 2005	Mar	NEWA
	AB1		100MG	N65110	002	Mar 29, 2005	Mar	NEWA

GENGRAF

	AB1	ABBOTT	50MG	N65003	002	May 12, 2000	Mar	CTEC

SOLUTION; ORAL
CYCLOSPORINE

	AB1	IVAX PHARMS	100MG/ML	N65078	001	Mar 25, 2005	Mar	NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL

		@ ABC HOLDING	4MG	N88212	001	May 26, 1983	Feb	DISC

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN

	+	PHARMACIA AND UPJOHN	7,500 IU/0.3ML	N20287	005	Apr 04, 2002	Jan	NEWA
>A>		@	7,500 IU/0.75ML	N20287	008	Apr 04, 2002	Apr	DISC
>A>		+	95,000IU/3.8ML(25,000IU/ML)	N20287	006	Apr 04, 2002	Apr	NEWA
>A>		+	95,000IU/9.5ML(10,000IU/ML)	N20287	007	Apr 04, 2002	Apr	NEWA

DANTROLENE SODIUM

CAPSULE; ORAL
DANTRIUM

	AB	PROCTER AND GAMBLE	25MG	N17443	001		Feb	CFTG
	AB		50MG	N17443	003		Feb	CFTG
	AB	+	100MG	N17443	002		Feb	CFTG

DANTROLENE SODIUM

	AB	IMPAX LABS	25MG	N76856	001	Mar 01, 2005	Feb	NEWA
	AB		50MG	N76856	002	Mar 01, 2005	Feb	NEWA
	AB		100MG	N76856	003	Mar 01, 2005	Feb	NEWA

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS
IPRIVASK

	+	CANYON	15MG/VIAL	N21271	001	Apr 04, 2003	Mar	CAIN

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARINEX D 24 HOUR

+	SCHERING	5MG;240MG	N21605	001	Mar 03, 2005	Mar	NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB	APOTEX	0.01MG/SPRAY	N76703	001	Jan 27, 2005	Jan	NEWA

DESONIDE

CREAM; TOPICAL
DESONIDE

AB	TEVA PHARMS	0.05%	N74027	001	Sep 28, 1992	Mar	CAHN

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE

	PAR PHARM	0.25MG	N88149	001	Apr 28, 1983	Mar	CRLD
BP	ROXANE	1.5MG	N84610	001		Mar	CRLD

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

>A>	AP	AM PHARM	EQ 10MG PHOSPHATE/ML	N40572	001	Apr 22, 2005	Apr	NEWA

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 50% IN PLASTIC CONTAINER

AP	HOSPIRA	500MG/ML	N19445	001	Jun 03, 1986	Mar	CMFD

DIAZEPAM

GEL; RECTAL
DIASTAT

>A>		VALEANT	2.5MG/0.5ML	N20648	001	Jul 29, 1997	Apr	CAHN
>A>			5MG/ML	N20648	002	Jul 29, 1997	Apr	CAHN
>A>			10MG/2ML	N20648	003	Jul 29, 1997	Apr	CAHN
>A>			15MG/3ML	N20648	004	Jul 29, 1997	Apr	CAHN
>A>	+		20MG/4ML	N20648	005	Jul 29, 1997	Apr	CAHN
>D>		XCEL PHARMS	2.5MG/0.5ML	N20648	001	Jul 29, 1997	Apr	CAHN
>D>			5MG/ML	N20648	002	Jul 29, 1997	Apr	CAHN
>D>			10MG/2ML	N20648	003	Jul 29, 1997	Apr	CAHN
>D>			15MG/3ML	N20648	004	Jul 29, 1997	Apr	CAHN
>D>	+		20MG/4ML	N20648	005	Jul 29, 1997	Apr	CAHN

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM

AB	TEVA PHARMS	25MG	N74459	001	Jun 25, 1997	Mar	CAHN
AB		50MG	N74459	002	Jun 25, 1997	Mar	CAHN
AB		75MG	N74459	003	Jun 25, 1997	Mar	CAHN

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL

BENTYL

AA	+	AXCAN SCANDIPHARM	10MG/5ML	N07961	002	Oct 15, 1984	Mar	CTEC

DICYCLOMINE HCL

AA		MIKART	10MG/5ML	N40169	001	Mar 24, 2005	Mar	NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HCL

		@ ABC HOLDING	25MG	N88267	001	Aug 25, 1983	Feb	DISC
		@	25MG	N88268	001	Aug 25, 1983	Feb	DISC

TENUATE

	+	AVENTIS PHARMS	25MG	N11722	002		Feb	CTEC

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

>A>	AP	+ VALEANT	1MG/ML	N05929	001		Apr	CAHN
>D>	AP	+ XCEL PHARMS	1MG/ML	N05929	001		Apr	CAHN

SPRAY, METERED; NASAL

MIGRANAL

>A>		+ VALEANT	0.5MG/INH	N20148	001	Dec 08, 1997	Apr	CAHN
>D>		+ XCEL PHARM	0.5MG/INH	N20148	001	Dec 08, 1997	Apr	CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

CARDIZEM

AP	+	BIOVAIL LABS INTL	5MG/ML	N20027	001	Oct 24, 1991	Mar	CAHN
	+		25MG/VIAL	N20027	003	Aug 18, 1995	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

		BIOVAIL LABS INTL	120MG	N21392	001	Feb 06, 2003	Mar	CAHN
			180MG	N21392	002	Feb 06, 2003	Mar	CAHN
			240MG	N21392	003	Feb 06, 2003	Mar	CAHN
			300MG	N21392	004	Feb 06, 2003	Mar	CAHN
			360MG	N21392	005	Feb 06, 2003	Mar	CAHN
	+		420MG	N21392	006	Feb 06, 2003	Mar	CAHN

TABLET; ORAL

CARDIZEM

AB		BIOVAIL LABS INTL	30MG	N18602	001	Nov 05, 1982	Mar	CAHN
AB			60MG	N18602	002	Nov 05, 1982	Mar	CAHN
AB			90MG	N18602	003	Dec 08, 1986	Mar	CAHN
AB	+		120MG	N18602	004	Dec 08, 1986	Mar	CAHN

DILTIAZEM HCL

AB		TEVA PHARMS	30MG	N74067	001	Nov 05, 1992	Mar	CAHN
AB			60MG	N74067	002	Nov 05, 1992	Mar	CAHN
AB			90MG	N74067	003	Nov 05, 1992	Mar	CAHN
AB			120MG	N74067	004	Nov 05, 1992	Mar	CAHN

DOXAZOSIN MESYLATE

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

		PFIZER	EQ 4MG BASE	N21269	001	Feb 22, 2005	Feb	NEWA
	+		EQ 8MG BASE	N21269	002	Feb 22, 2005	Feb	NEWA

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL

DOXEPIN HCL

AA		TEVA PHARMS	EQ 10MG BASE/ML	N71609	001	Nov 09, 1987	Mar	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB		PAR PHARM	EQ 75MG BASE	N65055	004	Apr 18, 2005	Mar	NEWA
AB		RANBAXY	EQ 75MG BASE	N65053	003	Sep 10, 2003	Mar	CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

>A>		+ WEST WARD	EQ 20MG BASE	N65103	001	May 13, 2005	Apr	NEWA

TABLET; ORAL

DOXYCYCLINE HYCLATE

>A>	AB	COREPHARMA	EQ 20MG BASE	N65182	001	May 13, 2005	Apr	NEWA
>A>	AB	IVAX PHARMS	EQ 20MG BASE	N65163	001	May 13, 2005	Apr	NEWA
>A>	AB	MUTUAL PHARMA	EQ 20MG BASE	N65134	001	May 13, 2005	Apr	NEWA

PERIOSTAT

>D>		+ COLLAGENEX PHARMS	20MG	N50783	001	Feb 02, 2001	Apr	CFTG
>A>	AB	+	EQ 20MG BASE	N50783	001	Feb 02, 2001	Apr	CFTG

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

		@ APOTHECON	2.5MG	N75583	001	Aug 22, 2000	Feb	DISC
		@	5MG	N75583	002	Aug 22, 2000	Feb	DISC
		@	10MG	N75583	003	Aug 22, 2000	Feb	DISC
		@	20MG	N75583	004	Aug 22, 2000	Feb	DISC

VASOTEC

AB		BIOVAIL LABS INTL	2.5MG	N18998	005	Jul 26, 1988	Mar	CAHN
AB			5MG	N18998	001	Dec 24, 1985	Mar	CAHN
AB			10MG	N18998	002	Dec 24, 1985	Mar	CAHN
AB	+		20MG	N18998	003	Dec 24, 1985	Mar	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB		BIOVAIL LABS INTL	5MG;12.5MG	N19221	003	Jul 12, 1995	Mar	CAHN
AB	+		10MG;25MG	N19221	001	Oct 31, 1986	Mar	CAHN

ENALAPRILAT

INJECTABLE; INJECTION

VASOTEC

AP	+	BIOVAIL LABS INTL	1.25MG/ML	N19309	001	Feb 09, 1988	Mar	CAHN

ENTECAVIR

SOLUTION; ORAL

BARACLUDE

	+	BRISTOL MYERS SQUIBB	0.05MG/ML	N21798	001	Mar 29, 2005	Mar	NEWA

TABLET; ORAL

BARACLUDE

		BRISTOL MYERS SQUIBB	0.5MG	N21797	001	Mar 29, 2005	Mar	NEWA

TABLET; ORAL
BARACLUDE
+ BRISTOL MYERS SQUIBB 1MG N21797 002 Mar 29, 2005 Mar NEWA

EPINEPHRINE

INJECTABLE; IM-SC
TWINJECT 0.30
+ HOLLISTER STIER LABS EQ 0.3MG /DELIVERY N20800 001 May 30, 2003 Feb CTNA

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYMAX
AT MERZ PHARMS 2% N62508 002 Jul 11, 1985 Jan CAHN

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE
@ BARR EQ 250MG BASE N62162 002 Feb DISC

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
ESMOLOL HCL
>A> AP AM PHARM 10MG/ML N76573 001 May 02, 2005 Apr NEWA
>A> AP PHARMAFORCE 10MG/ML N76474 001 May 02, 2005 Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL
NEXIUM
ASTRAZENECA EQ 20MG BASE N21153 001 Feb 20, 2001 Jan CRLD

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS
NEXIUM IV
+ ASTRAZENECA 20MG/VIAL N21689 001 Mar 31, 2005 Mar NEWA
+ 40MG/VIAL N21689 002 Mar 31, 2005 Mar NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA
AB2 + BERLEX 0.025MG/24HR N20375 004 Mar 05, 1999 Jan CFTG
AB2 + 0.075MG/24HR N20375 003 Mar 23, 1998 Jan CFTG
ESCLIM
@ WOMEN FIRST HLTHCARE 0.025MG/24HR N20847 001 Aug 04, 1998 Jan DISC
@ 0.0375MG/24HR N20847 002 Aug 04, 1998 Jan DISC
@ 0.05MG/24HR N20847 003 Aug 04, 1998 Jan DISC
@ 0.075MG/24HR N20847 004 Aug 04, 1998 Jan DISC
@ 0.1MG/24HR N20847 005 Aug 04, 1998 Jan DISC
ESTRADIOL
AB2 MYLAN TECHNOLOGIES 0.025MG/24HR N75182 003 Jan 26, 2005 Jan NEWA
AB2 0.075MG/24HR N75182 002 Jan 26, 2005 Jan NEWA
VIVELLE
@ NOVARTIS 0.025MG/24HR N20323 005 Aug 16, 2000 Jan DISC
AB1 0.05MG/24HR N20323 002 Oct 28, 1994 Jan CRLD
AB1 0.1MG/24HR N20323 004 Oct 28, 1994 Jan CRLD
VIVELLE-DOT
BX + NOVARTIS 0.025MG/24HR N20538 009 May 03, 2002 Jan CRLD

FILM, EXTENDED RELEASE; TRANSDERMAL

VIVELLE-DOT

BX	+	NOVARTIS	0.0375MG/24HR	N20538	005	Jan 08, 1999	Jan	CRLD
AB1	+		0.05MG/24HR	N20538	006	Jan 08, 1999	Jan	CRLD
BX	+		0.075MG/24HR	N20538	007	Jan 08, 1999	Jan	CRLD
AB1	+		0.1MG/24HR	N20538	008	Jan 08, 1999	Jan	CRLD

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

>A> AB		BARR	1MG,1MG;N/A,0.09MG	N76812	001	Apr 29, 2005	Apr	NEWA

PREFEST

>D>	+	DURAMED	1MG,1MG;0.09MG,N/A	N21040	001	Oct 22, 1999	Apr	CFTG
>A> AB	+		1MG,1MG;N/A,0.09MG	N21040	001	Oct 22, 1999	Apr	CFTG

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

	@	DURAMED	0.3MG	N21443	001	Dec 20, 2004	Mar	DISC
	@		0.45MG	N21443	002	Dec 20, 2004	Mar	DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

	+	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041	001	Sep 24, 1991	Mar	CTEC

NORTREL 7/7/7

		BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N75478	001	Aug 30, 2002	Mar	CTEC

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

		WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71042	001	Sep 24, 1991	Mar	CTEC

ORTHO-NOVUM 10/11-28

AB	+	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354	002	Jan 11, 1982	Mar	CRLD

ORTHO-NOVUM 7/14-28

	@	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N19004	002	Apr 04, 1984	Feb	DISC

OVCON-35

AB		WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		Mar	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>A> AB		ANDRX PHARMS	0.03MG;1.5MG	N77075	001	Apr 28, 2005	Apr	NEWA

ETHOSUXIMIDE

SYRUP; ORAL

ETHOSUXIMIDE

AA		TEVA PHARMS	250MG/5ML	N81306	001	Jul 30, 1993	Mar	CAHN

>A> EXENATIDE SYNTHETIC

>A> INJECTABLE; SUBCUTANEOUS

>A> BYETTA

>A>	+	AMYLIN	300UGM/1.2ML(250UGM/ML)	N21773	001	Apr 28, 2005	Apr	NEWA
>A>	+		600UGM/2.4ML(250UGM/ML)	N21773	002	Apr 28, 2005	Apr	NEWA

FENOFIBRATE

TABLET; ORAL

>A>			FENOFIBRATE						
>A>	AB		TEVA	54MG	N76433	001	May 13, 2005	Apr	NEWA
>A>	AB			160MG	N76433	002	May 13, 2005	Apr	NEWA
			TRICOR						
>D>			ABBOTT	54MG	N21203	001	Sep 04, 2001	Apr	CFTG
>A>	AB			54MG	N21203	001	Sep 04, 2001	Apr	CFTG
>D>		+		160MG	N21203	003	Sep 04, 2001	Apr	CFTG
>A>	AB	+		160MG	N21203	003	Sep 04, 2001	Apr	CFTG

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

			FENOLDOPAM MESYLATE						
	AP		SABEX 2002	EQ 10MG BASE/ML	N77155	001	Feb 15, 2005	Jan	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

			NALFON						
>A>	AB	+	PEDINOL	EQ 300MG BASE	N17604	002		Apr	CAHN
>D>	AB	+	RANBAXY	EQ 300MG BASE	N17604	002		Apr	CAHN
			NALFON 200						
>A>	AB		PEDINOL	EQ 200MG BASE	N17604	003		Apr	CAHN
>D>	AB		RANBAXY	EQ 200MG BASE	N17604	003		Apr	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

			DURAGESIC-100						
	AB		ALZA	100UGM/HR	N19813	001	Aug 07, 1990	Jan	CFTG
			DURAGESIC-12						
			ALZA	12.5UGM/HR	N19813	005	Feb 04, 2005	Feb	NEWA
			DURAGESIC-25						
	AB	+	ALZA	25UGM/HR	N19813	004	Aug 07, 1990	Jan	CFTG
			DURAGESIC-50						
	AB		ALZA	50UGM/HR	N19813	003	Aug 07, 1990	Jan	CFTG
			DURAGESIC-75						
	AB		ALZA	75UGM/HR	N19813	002	Aug 07, 1990	Jan	CFTG
			FENTANYL						
	AB		MYLAN TECHNOLOGIES	25UGM/HR	N76258	001	Jan 28, 2005	Jan	NEWA
	AB			50UGM/HR	N76258	002	Jan 28, 2005	Jan	NEWA
	AB			75UGM/HR	N76258	003	Jan 28, 2005	Jan	NEWA
	AB			100UGM/HR	N76258	004	Jan 28, 2005	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

			ALLEGRA-D 12 HOUR						
	AB	+	AVENTIS PHARMS	60MG;120MG	N20786	001	Dec 24, 1997	Mar	CFTG
			FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCL						
	AB		BARR	60MG;120MG	N76236	001	Apr 14, 2005	Mar	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

			FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER						
	AP		APOTEX	200MG/100ML	N76888	001	Mar 25, 2005	Mar	NEWA

INJECTABLE; INJECTION
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	AP		APOTEX	200MG/100ML	N76889	001	Mar 25, 2005	Mar	NEWA

FLUCYTOSINE

CAPSULE; ORAL
ANCOBON

>D>			ICN	250MG	N17001	001		Apr	CAHN
>D>		+		500MG	N17001	002		Apr	CAHN
>A>			VALEANT	250MG	N17001	001		Apr	CAHN
>A>		+		500MG	N17001	002		Apr	CAHN

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL

>A>	AP		SABEX 2002	0.5MG/5ML (0.1MG/ML)	N77071	001	May 03, 2005	Apr	NEWA
>A>	AP			1MG/10ML (0.1MG/ML)	N77071	002	May 03, 2005	Apr	NEWA

FLUOCINOLONE ACETONIDE

IMPLANT; INTRAVITREAL
RETISERT

>A>		+	BAUSCH AND LOMB	0.59MG	N21737	001	Apr 08, 2005	Apr	NEWA

FLUOCINONIDE

CREAM; TOPICAL
VANOS

		+	MEDICIS	0.1%	N21758	001	Feb 11, 2005	Feb	NEWA

SOLUTION; TOPICAL
FLUOCINONIDE

	AT		TEVA PHARMS	0.05%	N72522	001	Sep 28, 1990	Mar	CAHN

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

>D>	AP	+	ICN PUERTO RICO	50MG/ML	N12209	001		Apr	CAHN
>A>	AP	+	VALEANT	50MG/ML	N12209	001		Apr	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
FLUOXETINE

>A>	AB		BARR	EQ 40MG BASE	N76251	001	May 18, 2005	Apr	NEWA

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
FLUPHENAZINE HCL

	AA		TEVA PHARMS	5MG/ML	N73058	001	Aug 30, 1991	Mar	CAHN

ELIXIR; ORAL
FLUPHENAZINE HCL

	AA		TEVA PHARMS	2.5MG/5ML	N81310	001	Apr 29, 1993	Mar	CAHN

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION
FLOVENT

		+	GLAXOSMITHKLINE	0.044MG/INH	N20548	001	Mar 27, 1996	Jan	CRLD
		+		0.11MG/INH	N20548	002	Mar 27, 1996	Jan	CRLD

		AEROSOL, METERED; INHALATION							
		FLOVENT HFA							
	+	GLAXOSMITHKLINE	0.044MG/INH	N21433	003	May 14, 2004	Jan	CRLD
	+		0.11MG/INH	N21433	002	May 14, 2004	Jan	CRLD
		LOTION; TOPICAL							
		CUTIVATE							
	+	GLAXOSMITHKLINE	0.05%	N21152	001	Mar 31, 2005	Mar	NEWA
		FOLLITROPIN ALFA/BETA							
		INJECTABLE; SUBCUTANEOUS							
		FOLLISTIM AQ							
	+	ORGANON USA INC	150 IU/0.18ML	N21211	003	Feb 11, 2004	Feb	NEWA
	+		300 IU/0.36ML	N21211	001	Mar 23, 2004	Jan	CPOT
	+		600 IU/0.72ML	N21211	002	Mar 23, 2004	Jan	CPOT
	+		900 IU/1.08ML	N21211	004	Feb 11, 2005	Feb	NEWA
		FOMIVIRSEN SODIUM							
		INJECTABLE; INJECTION							
		VITRAVENE PRESERVATIVE FREE							
	@	NOVARTIS	6.6MG/ML	N20961	001	Aug 26, 1998	Feb	DISC
		FOSINOPRIL SODIUM							
		TABLET; ORAL							
		FOSINOPRIL SODIUM							
>A>	AB	APOTEX	10MG	N76906	001	May 17, 2005	Apr	NEWA
>A>	AB		20MG	N76906	002	May 17, 2005	Apr	NEWA
>A>	AB		40MG	N76906	003	May 17, 2005	Apr	NEWA
	AB	INVAGEN PHARMS	10MG	N77222	001	Apr 20, 2005	Mar	NEWA
	AB		20MG	N77222	002	Apr 20, 2005	Mar	NEWA
	AB		40MG	N77222	003	Apr 20, 2005	Mar	NEWA
		FUROSEMIDE							
		INJECTABLE; INJECTION							
		FUROSEMIDE							
	AP +	LUITPOLD	10MG/ML	N18579	001	Nov 30, 1983	Feb	CRLD
		LASIX							
	@	AVENTIS PHARMS	10MG/ML	N16363	001		Feb	DISC
		GABAPENTIN							
		CAPSULE; ORAL							
		GABAPENTIN							
	AB	APOTEX	100MG	N75360	001	Apr 06, 2005	Mar	NEWA
	AB		300MG	N75360	002	Apr 06, 2005	Mar	NEWA
	AB		400MG	N75360	003	Apr 06, 2005	Mar	NEWA
	AB	EON	100MG	N75539	001	Apr 06, 2005	Mar	NEWA
	AB		300MG	N75539	002	Apr 06, 2005	Mar	NEWA
	AB		400MG	N75539	003	Apr 06, 2005	Mar	NEWA
	AB	IVAX PHARMS	100MG	N75477	001	Mar 23, 2005	Mar	NEWA
	AB		300MG	N75477	002	Mar 23, 2005	Mar	NEWA
	AB		400MG	N75477	003	Mar 23, 2005	Mar	NEWA
		TABLET; ORAL							
		GABAPENTIN							
>A>	AB	IVAX PHARMS	600MG	N76017	004	Apr 29, 2005	Apr	NEWA
>A>	AB		800MG	N76017	005	Apr 29, 2005	Apr	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

REMINYL

+	JOHNSON AND JOHNSON	EQ 8MG BASE	N21615	001	Dec 22, 2004	Jan	CRLD
		EQ 24MG BASE	N21615	003	Dec 22, 2004	Jan	CRLD

GATIFLOXACIN

INJECTABLE; INJECTION

TEQUIN

+	BRISTOL MYERS SQUIBB	400MG/40ML(10MG/ML)	N21062	004	Dec 17, 1999	Mar	CPOT

TEQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	BRISTOL MYERS SQUIBB	200MG/100ML(2MG/ML)	N21062	001	Dec 17, 1999	Mar	CPOT
+		400MG/200ML(2MG/ML)	N21062	002	Dec 17, 1999	Mar	CPOT

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HCL

AB	TEVA	1.25MG;250MG	N76821	001	Jan 27, 2005	Jan	NEWA
AB		2.5MG;500MG	N76821	002	Jan 27, 2005	Jan	NEWA
AB		5MG;500MG	N76821	003	Jan 27, 2005	Jan	NEWA

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

>D>	AB	COREPHARMA	1MG	N40568	001	Dec 22, 2004	Apr	CTEC
>A>	AA		1MG	N40568	001	Dec 22, 2004	Apr	CTEC
>D>	AB		2MG	N40568	002	Dec 22, 2004	Apr	CTEC
>A>	AA		2MG	N40568	002	Dec 22, 2004	Apr	CTEC

ROBINUL

>D>	AB	+	FIRST HORIZON	1MG	N12827	001		Apr	CTEC
>A>	AA	+		1MG	N12827	001		Apr	CTEC

ROBINUL FORTE

>D>	AB	+	FIRST HORIZON	2MG	N12827	002		Apr	CTEC
>A>	AA	+		2MG	N12827	002		Apr	CTEC

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

	@ WATSON LABS (UTAH)	2,000 UNITS/VIAL	N17016	009	Dec 27, 1984	Feb	CAHN
	@	2,000 UNITS/VIAL	N17016	011	Feb 16, 1990	Feb	CAHN
	@	5,000 UNITS/VIAL	N17016	006		Feb	CAHN
AP	+	10,000 UNITS/VIAL	N17016	007		Feb	CAHN
	@	15,000 UNITS/VIAL	N17016	010	Feb 15, 1985	Feb	CAHN
	@	20,000 UNITS/VIAL	N17016	004		Feb	CAHN

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+	J AND J	125MG/5ML	N62483	001	Jan 26, 1984	Feb	CFTG

GRISEOFULVIN

AB	STIEFEL	125MG/5ML	N65200	001	Mar 02, 2005	Feb	NEWA

GUANABENZ ACETATE

TABLET; ORAL

		GUANABENZ ACETATE						
AB		TEVA PHARMS	EQ 4MG BASE	N74267	001	Jun 01, 1994	Mar	CAHN
AB			EQ 8MG BASE	N74267	002	Jun 01, 1994	Mar	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

		HALOPERIDOL						
AA	+	TEVA PHARMS	EQ 2MG BASE/ML	N71617	001	Dec 01, 1988	Mar	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE						
AA		IVAX PHARMS	1.5MG/5ML;5MG/5ML	N40285	001	Jul 19, 1999	Jan	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

		HYDRALAZINE HCL						
		@ ABC HOLDING	10MG	N88846	001	Feb 26, 1985	Feb	DISC
		@	25MG	N88847	001	Feb 26, 1985	Feb	DISC
		@	50MG	N88848	001	Feb 26, 1985	Feb	DISC
		@	100MG	N88849	001	Feb 26, 1985	Feb	DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

		HYDROCHLOROTHIAZIDE						
		@ ABC HOLDING	25MG	N85683	001		Feb	DISC
		@	50MG	N83965	001		Feb	DISC
		@	50MG	N85672	001		Feb	DISC
>D>	AB	IVAX PHARMS	50MG	N83177	002		Apr	CRLD
>A>	AB	+	50MG	N83177	002		Apr	CRLD
>D>	AB	+	100MG	N85022	001		Apr	DISC
>A>		@	100MG	N85022	001		Apr	DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

		AVALIDE						
		SANOFI SYNTHELABO	12.5MG;300MG	N20758	003	Aug 31, 1998	Mar	CRLD
	+		25MG;300MG	N20758	004	Mar 15, 2005	Mar	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

		QUINAPRIL HCL AND HYDROCHLOROTHIAZIDE						
AB		MYLAN	12.5MG;EQ 10MG BASE	N77093	001	Mar 28, 2005	Mar	NEWA
AB			12.5MG;EQ 20MG BASE	N77093	002	Mar 28, 2005	Mar	NEWA
AB			25MG;EQ 20MG BASE	N77093	003	Mar 28, 2005	Mar	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

		DIOVAN HCT						
		NOVARTIS	12.5MG;160MG	N20818	002	Mar 06, 1998	Mar	CRLD
	+		25MG;160MG	N20818	003	Jan 17, 2002	Mar	CRLD

HYDROCORTISONE

ENEMA; RECTAL

HYDROCORTISONE

AB		TEVA PHARMS	100MG/60ML	N74171	001	May 27, 1994	Mar	CAHN

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB		TEVA PHARMS	0.2%	N74489	001	Aug 12, 1998	Mar	CAHN

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

		PURDUE PHARMA LP	16MG	N21044	002	Sep 24, 2004	Feb	CRLD
	+		32MG	N21044	004	Sep 24, 2004	Feb	CRLD

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB		TEVA PHARMS	200MG	N40081	001	Sep 30, 1994	Mar	CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

	@	WATSON LABS	125MG/ML	N17439	001		Mar	CAHN
	@		250MG/ML	N17439	002		Mar	CAHN

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

	+	ROCHE	EQ 2.5MG BASE	N21455	001	May 16, 2003	Feb	CMFD
>D>			EQ 150MG BASE	N21455	002	Mar 24, 2005	Apr	CRLD
>A>	+		EQ 150MG BASE	N21455	002	Mar 24, 2005	Apr	CRLD
			EQ 150MG BASE	N21455	002	Mar 24, 2005	Mar	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HCL

	@	TEVA	10MG	N83729	001		Feb	DISC
	@		25MG	N83729	004		Feb	DISC
	@		50MG	N83729	003		Feb	DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>A>	AN	BREATH LTD	0.02%	N76291	001	May 09, 2005	Apr	NEWA

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

	BP	+ WATSON LABS (UTAH)	EQ 50MG IRON/ML	N17441	001		Feb	CAHN

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

+	LUITPOLD	EQ 100MG BASE/5ML(EQ 20MG BASE/ML)	N21135	001	Nov 06, 2000	Mar	CPOT
		EQ 50MG BASE/2.5ML(EQ 20MG BASE/ML)	N21135	002	Mar 20, 2005	Mar	NEWA
		EQ 75MG BASE/3.75ML(EQ 20MG BASE/ML)	N21135	003	Mar 29, 2005	Mar	NEWA

ISRADIPINE

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

RELIANT PHARMS	5MG	N20336	001	Jun 01, 1994	Mar	CRLD

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

@ APOTHECON	EQ 500MG BASE	N62726	001	Mar 06, 1987	Feb	DISC

KETOCONAZOLE

SHAMPOO; TOPICAL

KETOCONAZOLE

AB	QLT USA	2%	N76942	001	Apr 11, 2005	Mar	NEWA

LACTULOSE

SOLUTION; ORAL

EVALOSE

AA	TEVA PHARMS	10GM/15ML	N73497	001	May 28, 1993	Mar	CAHN

SOLUTION; ORAL, RECTAL

HEPTALAC

AA	TEVA PHARMS	10GM/15ML	N73504	001	May 28, 1993	Mar	CAHN

LEPIRUDIN RECOMBINANT

INJECTABLE; INJECTION

REFLUDAN

+	BERLEX	50MG/VIAL	N20807	001	Mar 06, 1998	Mar	CAIN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE

>D>	AP		BEDFORD	EQ 10MG BASE/ML	N40347	001	Apr 25, 2000	Apr	CRLD
>A>	AP	+		EQ 10MG BASE/ML	N40347	001	Apr 25, 2000	Apr	CRLD
>D>	AP	+	HOSPIRA	EQ 10MG BASE/ML	N40147	001	Jun 25, 1997	Apr	DISC
>A>			@	EQ 10MG BASE/ML	N40147	001	Jun 25, 1997	Apr	DISC

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD

+	QLT USA	22.5MG/VIAL	N21379	001	Jul 24, 2002	Jan	CAHN

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+	SEPRACOR	EQ 0.045MG BASE/INH	N21730	001	Mar 11, 2005	Mar	NEWA

LEVOFLOXACIN

TABLET; ORAL

LEVAQUIN

	ORTHO MCNEIL PHARM	250MG	N20634	001	Dec 20, 1996	Mar	CTEC
		500MG	N20634	002	Dec 20, 1996	Mar	CTEC
AB +		750MG	N20634	003	Sep 08, 2000	Jan	CFTG

LEVOFLOXACIN

AB	TEVA	750MG	N76361	003	Jan 26, 2005	Jan	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL PRESERVATIVE FREE

>A> AP	AM PHARM	2%	N17584	001		Apr	CAHN
>A> AP		4%	N17584	002		Apr	CAHN
>D> AP	AM PHARM PARTNERS	2%	N17584	001		Apr	CAHN
>D> AP		4%	N17584	002		Apr	CAHN

JELLY; TOPICAL

LIDOCAINE HCL

AT	TEVA PHARMS	2%	N81318	001	Apr 29, 1993	Mar	CAHN

LORAZEPAM

SOLUTION; ORAL

LORAZEPAM

	ROXANE	0.5MG/5ML	N74648	001	Mar 18, 1997	Jan	CMFD

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

>D>	+ BERTEK PHARMS	EQ 85MG BASE/GM	N16763	001		Apr	CAHN
>A>	+ MYLAN BERTEK	EQ 85MG BASE/GM	N16763	001		Apr	CAHN

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

	@ GE HEALTHCARE	37.9MG/ML	N20652	001	Nov 26, 1997	Jan	DISC

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

AB	TEVA PHARMS	100MG	N73580	001	Jan 04, 1995	Mar	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HCL

	@ ABC HOLDING	12.5MG	N85253	001		Feb	DISC
	@	25MG	N85252	001		Feb	DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB	TEVA PHARMS	40MG/ML	N75681	001	May 05, 2003	Mar	CAHN

MEMANTINE HYDROCHLORIDE

>A>		SOLUTION; ORAL							
>A>		NAMENDA							
>A>	+	FOREST LABS	2MG/ML	N21627	001	Apr 18, 2005	Apr	NEWA	

MEQUINOL; TRETINOIN

		SOLUTION; TOPICAL							
		SOLAGE							
	+	BARRIER	2%;0.01%	N20922	001	Dec 10, 1999	Feb	CAHN	

METAPROTERENOL SULFATE

		SYRUP; ORAL							
		METAPROTERENOL SULFATE							
		@ TEVA PHARMS	10MG/5ML	N73034	001	Aug 30, 1991	Mar	CAHN	

METFORMIN HYDROCHLORIDE

		TABLET, EXTENDED RELEASE; ORAL							
		METFORMIN HCL							
	AB	ANDRX PHARMS	750MG	N76869	001	Apr 12, 2005	Mar	NEWA	
	AB	PUREPAC PHARM	750MG	N76878	001	Apr 13, 2005	Mar	NEWA	
	AB	TEVA	750MG	N76864	001	Apr 12, 2005	Mar	NEWA	
	AB	ZYDUS PHARMS USA	500MG	N77060	001	Apr 20, 2005	Mar	NEWA	
>A>	AB		750MG	N77078	001	Apr 21, 2005	Apr	NEWA	
		TABLET; ORAL							
		METFORMIN HCL							
	AB	ZYDUS PHARMS USA	500MG	N77064	001	Apr 18, 2005	Mar	NEWA	
	AB		850MG	N77064	002	Apr 18, 2005	Mar	NEWA	
	AB		1GM	N77064	003	Apr 18, 2005	Mar	NEWA	

METHAZOLAMIDE

		TABLET; ORAL							
		METHAZOLAMIDE							
	AB	TEVA PHARMS	25MG	N40001	001	Jun 30, 1993	Mar	CAHN	
	AB		50MG	N40001	002	Jun 30, 1993	Mar	CAHN	

METHIMAZOLE

		TABLET; ORAL							
		METHIMAZOLE							
	AB	CEDAR PHARMS	5MG	N40547	001	Feb 18, 2005	Jan	NEWA	
	AB		10MG	N40547	002	Feb 18, 2005	Jan	NEWA	
	AB		20MG	N40547	004	Feb 18, 2005	Jan	NEWA	
>D>	AB	+ GENPHARM	20MG	N40350	003	Jun 07, 2001	Apr	DISC	
>A>		@	20MG	N40350	003	Jun 07, 2001	Apr	DISC	
	AB	+	20MG	N40350	003	Jun 07, 2001	Jan	CFTG	

METHOTREXATE SODIUM

		INJECTABLE; INJECTION							
		METHOTREXATE							
>D>	AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40263	001	Feb 26, 1999	Apr	DISC	
>A>		@	EQ 25MG BASE/ML	N40263	001	Feb 26, 1999	Apr	DISC	
>A>	AP	+ MAYNE PHARMA USA	EQ 50MG BASE/2ML (25 MG/ML)	N11719	010	Dec 15, 2004	Apr	NEWA	
		METHOTREXATE LPF							
>D>	AP	+ MAYNE PHARMA USA	EQ 25MG BASE/ML	N11719	007	Mar 31, 1982	Apr	DISC	
>A>		@	EQ 25MG BASE/ML	N11719	007	Mar 31, 1982	Apr	DISC	

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

>D>	AP		BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40265	001	Feb 26, 1999	Apr	DISC
>A>		@		EQ 25MG BASE/ML	N40265	001	Feb 26, 1999	Apr	DISC
>D>	AP			EQ 1GM BASE/VIAL	N40266	001	Feb 26, 1999	Apr	DISC
>A>		@		EQ 1GM BASE/VIAL	N40266	001	Feb 26, 1999	Apr	DISC
>A>		+	MAYNE PHARMA USA	EQ 20MG BASE/2ML (10 MG/ML)	N11719	014	Apr 13, 2005	Apr	NEWA
>A>	AP	+		EQ 500MG BASE/20ML (25 MG/ML)	N11719	013	Apr 13, 2005	Apr	NEWA
>A>	AP	+		ED 1GM BASE/40ML (25 MG/ML)	N11719	012	Apr 13, 2005	Apr	NEWA
>A>	AP	+		EQ 2.5GM BASE/100ML (25 MG/ML)	N11719	011	Apr 13, 2005	Apr	NEWA

METHOTREXATE SODIUM

>D>	AP		BEDFORD	EQ 25MG BASE/ML	N89340	001	Sep 16, 1986	Apr	CPOT
>A>	AP			EQ 50 MG BASE/2ML (25 ML/ML)	N89340	001	Sep 16, 1986	Apr	CPOT
>D>	AP			EQ 25MG BASE/ML	N89341	001	Sep 16, 1986	Apr	CPOT
>A>	AP			EQ 100MG BASE/4ML (25 MG/ML)	N89341	001	Sep 16, 1986	Apr	CPOT
>D>	AP			EQ 25MG BASE/ML	N89342	001	Sep 16, 1986	Apr	CPOT
>A>	AP			EQ 200MG BASE/8ML (25 MG/ML)	N89342	001	Sep 16, 1986	Apr	CPOT
>D>	AP			EQ 25MG BASE/ML	N89343	001	Sep 16, 1986	Apr	CPOT
>A>	AP			EQ 250MG BASE/10ML (25 MG/ML)	N89343	001	Sep 16, 1986	Apr	CPOT
		@	MAYNE PHARMA USA	EQ 20MG BASE/VIAL	N11719	001		Mar	DISC
>D>	AP	+		EQ 25MG BASE/ML	N11719	005		Apr	DISC
>A>		@		EQ 25MG BASE/ML	N11719	005		Apr	DISC
>D>	AP		NORBROOK	EQ 25MG BASE/ML	N88648	001	May 09, 1986	Apr	DISC
>A>		@		EQ 25MG BASE/ML	N88648	001	May 09, 1986	Apr	DISC
>D>	AP		PHARMACHEMIE USA	EQ 25MG BASE/ML	N89158	001	Jul 08, 1988	Apr	DISC
>A>		@		EQ 25MG BASE/ML	N89158	001	Jul 08, 1988	Apr	DISC

MEXATE-AQ

>D>	AP		BRISTOL MYERS	EQ 25MG BASE/ML	N88760	001	Feb 14, 1985	Apr	DISC
>A>		@		EQ 25MG BASE/ML	N88760	001	Feb 14, 1985	Apr	DISC

METHYLDOPA

TABLET; ORAL

ALDOMET

		@	MERCK	500MG	N13400	002		Jan	DISC

METHYLDOPA

AB		+	MYLAN	500MG	N70076	001	Apr 18, 1985	Jan	CRLD

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

		@	MERCK	50MG/ML	N13401	001		Jan	DISC

METHYLDOPATE HCL

AP		+	LUITPOLD	50MG/ML	N71279	001	Oct 02, 1987	Jan	CRLD

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

		+	NOVARTIS	0.2MG	N06035	003		Jan	CRLD

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

AB		+	PHARMACIA AND UPJOHN	40MG/ML	N11757	001		Feb	CFTG
AB		+		80MG/ML	N11757	004		Feb	CFTG

METHYLPREDNISOLONE ACETATE

AB			SICOR PHARMS	40MG/ML	N40557	001	Feb 23, 2005	Feb	NEWA
AB				80MG/ML	N40557	002	Feb 23, 2005	Feb	NEWA

METOLAZONE

TABLET; ORAL
ZAROXOLYN

AB		UCB	2.5MG	N17386	001		Mar	CAHN
AB	+		5MG	N17386	002		Mar	CAHN
AB	+		10MG	N17386	003		Mar	CAHN

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB		TEVA PHARMS	50MG	N74333	001	Jan 27, 1994	Mar	CAHN
AB			100MG	N74333	002	Jan 27, 1994	Mar	CAHN

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)
MYCAMINE

	+	ASTELLAS	50MG/VIAL	N21506	002	Mar 16, 2005	Mar	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP		HOSPIRA	EQ 1MG BASE/ML	N75293	001	Jun 20, 2000	Mar	CMFD
AP			EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	Mar	CMFD
AP		INTL MEDICATED	EQ 1MG BASE/ML	N76144	001	Jan 26, 2005	Jan	NEWA
AP			EQ 5MG BASE/ML	N76144	002	Jan 26, 2005	Jan	NEWA

SYRUP; ORAL
MIDAZOLAM HCL

>A> AA		PADDOCK	EQ 2MG BASE/ML	N76379	001	May 02, 2005	Apr	NEWA

MOMETASONE FUROATE

CREAM; TOPICAL
ELOCON

AB	+	SCHERING	0.1%	N19625	001	May 06, 1987	Jan	CFTG

MOMETASONE FUROATE

AB		ALTANA	0.1%	N76171	001	Apr 08, 2005	Mar	NEWA
AB		TARO	0.1%	N76679	001	Dec 21, 2004	Jan	NEWA

LOTION; TOPICAL
ELOCON

AB	+	SCHERING	0.1%	N19796	001	Mar 30, 1989	Mar	CFTG

MOMETASONE FUROATE

AB		AGIS INDS	0.1%	N77180	001	Apr 06, 2005	Mar	NEWA

OINTMENT; TOPICAL
MOMETASONE FUROATE

AB		ALTANA	0.1%	N77061	001	Mar 28, 2005	Mar	NEWA

POWDER; INHALATION
ASMANEX TWISTHALER

	+	SCHERING	0.22MG/INH	N21067	001	Mar 30, 2005	Mar	NEWA

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL
NASONEX

>A>	+	SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY	N20762	001	Oct 01, 1997	Apr	CAHN
>D>	+	SHIRE	EQ 0.05MG BASE/SPRAY	N20762	001	Oct 01, 1997	Apr	CAHN
	+		EQ 0.05MG BASE/SPRAY	N20762	001	Oct 01, 1997	Mar	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

BX	LIGAND	30MG	N21260	001	Mar 20, 2002	Mar	CRLD
BX		60MG	N21260	002	Mar 20, 2002	Mar	CRLD
		90MG	N21260	003	Mar 20, 2002	Mar	CRLD

KADIAN

	ALPHARMA US PHARMS	20MG	N20616	001	Jul 03, 1996	Mar	CRLD
BX		30MG	N20616	004	Mar 09, 2001	Mar	CRLD
		50MG	N20616	002	Jul 03, 1996	Mar	CRLD
BX		60MG	N20616	005	Mar 09, 2001	Mar	CRLD

NADOLOL

TABLET; ORAL

NADOLOL

AB	TEVA PHARMS	80MG	N74368	001	Aug 31, 1994	Mar	CAHN
AB		120MG	N74368	002	Aug 31, 1994	Mar	CAHN
AB		160MG	N74368	003	Aug 31, 1994	Mar	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

AP	HOSPIRA	0.4MG/ML	N70172	001	Sep 24, 1986	Mar	CMFD

NAPROXEN

TABLET; ORAL

NAPROXEN

>A> AB	PERRIGO R AND D	250MG	N77339	001	Apr 27, 2005	Apr	NEWA
>A> AB		375MG	N77339	002	Apr 27, 2005	Apr	NEWA
>A> AB		500MG	N77339	003	Apr 27, 2005	Apr	NEWA
AB	TEVA PHARMS	250MG	N74207	001	Dec 21, 1993	Mar	CAHN
AB		375MG	N74207	002	Dec 21, 1993	Mar	CAHN
AB		500MG	N74207	003	Dec 21, 1993	Mar	CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB	TEVA PHARMS	EQ 250MG BASE	N74289	001	Jan 27, 1994	Mar	CAHN
AB		EQ 500MG BASE	N74289	002	Jan 27, 1994	Mar	CAHN

>D> NESIRITIDE

>D> FOR SOLUTION; INTRAVENOUS

>D> NATRECOR

>D> +	SCIOS	1.5MG/VIAL	N20920	001	Aug 10, 2001	Apr	CAIN

>A> NESIRITIDE RECOMBINANT

>A> FOR SOLUTION; INTRAVENOUS

>A> NATRECOR

>A> +	SCIOS	1.5MG/VIAL	N20920	001	Aug 10, 2001	Apr	CAIN

NIACIN

TABLET, EXTENDED RELEASE; ORAL

>A> NIACIN

>A> AB	BARR	500MG	N76378	001	Apr 26, 2005	Apr	NEWA
>A> AB		750MG	N76378	002	Apr 26, 2005	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

NIACIN

>A>		BARR	1GM	N76250	001	Apr 14, 2005	Mar	NEWA

NIASPAN

>D>	+	KOS	500MG	N20381	002	Jul 28, 1997	Apr	CFTG
>A>	AB +		500MG	N20381	002	Jul 28, 1997	Apr	CFTG
>D>	+		750MG	N20381	003	Jul 28, 1997	Apr	CFTG
>A>	AB +		750MG	N20381	003	Jul 28, 1997	Apr	CFTG
	AB +		1GM	N20381	004	Jul 28, 1997	Mar	CFTG

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARDENE

	+	ESP PHARMA	2.5MG/ML	N19734	001	Jan 30, 1992	Mar	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

	AB	EON	75MG;25MG	N77066	001	Apr 05, 2005	Mar	NEWA
	AB	RANBAXY	75MG;25MG	N76951	001	Mar 30, 2005	Mar	NEWA

NYSTATIN

POWDER; TOPICAL

NYSTATIN

>A>	AT	UPSHER SMITH	100,000 UNITS/GM	N65183	001	May 03, 2005	Apr	NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

	AP	BEDFORD	EQ 0.2MG BASE/ML	N76330	001	Apr 08, 2005	Mar	NEWA
	AP		EQ 1MG BASE/ML	N76330	002	Apr 08, 2005	Mar	NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

	AP	BEDFORD	EQ 0.05MG BASE/ML	N76313	001	Mar 28, 2005	Mar	NEWA
	AP		EQ 0.1MG BASE/ML	N76313	003	Mar 28, 2005	Mar	NEWA
	AP		EQ 0.5MG BASE/ML	N76313	002	Mar 28, 2005	Mar	NEWA

SANDOSTATIN

	AP +	NOVARTIS	EQ 0.05MG BASE/ML	N19667	001	Oct 21, 1988	Mar	CFTG
	AP +		EQ 0.1MG BASE/ML	N19667	002	Oct 21, 1988	Mar	CFTG
	AP +		EQ 0.2MG BASE/ML	N19667	004	Jun 12, 1991	Mar	CFTG
	AP +		EQ 0.5MG BASE/ML	N19667	003	Oct 21, 1988	Mar	CFTG
	AP +		EQ 1MG BASE/ML	N19667	005	Jun 12, 1991	Mar	CFTG

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

	+	UCB	250MG	N19715	001	Jul 31, 1990	Mar	CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PRILOSEC

>D>		ASTRAZENECA	40MG	N19810	002	Jan 15, 1998	Apr	CRLD
>A>	+		40MG	N19810	002	Jan 15, 1998	Apr	CRLD
			40MG	N19810	002	Jan 15, 1998	Mar	CTEC

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

+	SANOFI	50MG/VIAL	N21492	001	Aug 09, 2002	Mar	CRLD
+	SANOFI SYNTHELABO	50MG/10ML (5MG/ML)	N21759	001	Jan 31, 2005	Jan	NEWA
+		100MG/20ML (5MG/ML)	N21759	002	Jan 31, 2005	Jan	NEWA

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

>D>	AB	IVAX PHARMS	30MG	N70945	001	Aug 03, 1987	Apr	CRLD
>A>	AB	+	30MG	N70945	001	Aug 03, 1987	Apr	CRLD

>D> SERAX

>D>	AB	ALPHARMA US PHARMS	10MG	N15539	002		Apr	DISC
>A>		@	10MG	N15539	002		Apr	DISC
>D>	AB		15MG	N15539	004		Apr	DISC
>A>		@	15MG	N15539	004		Apr	DISC
>D>	AB	+	30MG	N15539	006		Apr	DISC
>A>		@	30MG	N15539	006		Apr	DISC

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

+	AM BIOSCIENCE	100MG/VIAL	N21660	001	Jan 07, 2005	Jan	NEWA

PEMOLINE

TABLET, CHEWABLE; ORAL

PEMOLINE

AB	TEVA PHARMS	37.5MG	N75555	001	Feb 18, 2000	Mar	CAHN

TABLET; ORAL

PEMOLINE

AB	TEVA PHARMS	18.75MG	N75030	003	Feb 22, 2000	Mar	CAHN
AB		37.5MG	N75030	001	Jan 29, 1999	Mar	CAHN
AB		75MG	N75030	002	Jan 29, 1999	Mar	CAHN

PENTOBARBITAL SODIUM

CAPSULE; ORAL

SODIUM PENTOBARBITAL

@	VALEANT PHARM INTL	100MG	N83264	001		Jan	DISC

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

BONTRIL PDM

AA	+	VALEANT	35MG	N85272	001		Feb	CRLD

CAM-METRAZINE

	@	ABC HOLDING	35MG	N83922	001		Feb	DISC
	@		35MG	N85318	001		Feb	DISC
	@		35MG	N85320	001		Feb	DISC
	@		35MG	N85321	001		Feb	DISC
	@		35MG	N85511	001		Feb	DISC
	@	CAMALL	35MG	N85756	001		Feb	DISC

PHENDIMETRAZINE TARTRATE

	@	ABC HOLDING	35MG	N85761	001		Feb	DISC
	@		35MG	N85941	001	Jun 27, 1983	Feb	DISC
	@	EON	35MG	N85830	001		Feb	DISC

TABLET; ORAL
X-TROZINE
@ SHIRE RICHWOOD 35MG N86553 001 Feb DISC
@ 35MG N86554 001 Feb DISC

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
ONA-MAST
@ MAST MM 30MG N86511 001 Feb DISC
@ 30MG N86516 001 Feb DISC
PHENTERMINE HCL
@ ABC HOLDING 18.75MG N88576 001 May 23, 1984 Feb DISC
@ 30MG N85417 001 Feb DISC
@ 30MG N86732 002 Feb DISC
@ 30MG N87215 001 Feb DISC
@ 37.5MG N87915 001 Dec 22, 1983 Feb DISC
@ 37.5MG N87918 001 Dec 22, 1983 Feb DISC
@ 37.5MG N87930 001 Oct 14, 1983 Feb DISC
@ 37.5MG N88610 001 Jun 04, 1984 Feb DISC
@ 37.5MG N88611 001 Jun 04, 1984 Feb DISC
@ 37.5MG N88625 001 Aug 23, 1984 Feb DISC
@ CAMALL 15MG N86735 001 Feb DISC
@ 30MG N87226 001 Feb DISC

TABLET; ORAL
ONA MAST
@ MAST MM 8MG N86260 001 Feb DISC
PHENTERMINE HCL
@ ABC HOLDING 8MG N83923 001 Feb DISC
@ 8MG N85319 001 Feb DISC
@ 37.5MG N87805 001 Dec 06, 1982 Feb DISC
@ 37.5MG N88596 001 Apr 04, 1984 Feb DISC
AA LANNETT 37.5MG N40555 001 Apr 15, 2005 Mar NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
IONAMIN
UCB EQ 15MG BASE N11613 004 Mar CAHN
\+ EQ 30MG BASE N11613 002 Mar CAHN

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN
AP + ELKINS SINN 50MG/ML N84307 001 Mar CTEC
PHENYTOIN SODIUM
AP HOSPIRA 50MG/ML N89521 001 Mar 17, 1987 Mar CMFD
AP 50MG/ML N89744 001 Dec 18, 1987 Mar CMFD

PIROXICAM

CAPSULE; ORAL
PIROXICAM
AB TEVA PHARMS 10MG N74103 001 Aug 28, 1992 Mar CAHN
AB 20MG N74103 002 Aug 28, 1992 Mar CAHN

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP		HOSPIRA	14.9MG/ML	N20161	005	Nov 30, 1992	Mar	CMFD
AP			745MG/100ML	N20161	001	Nov 30, 1992	Mar	CMFD

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP		HOSPIRA	1.49GM/100ML	N20161	002	Nov 30, 1992	Mar	CMFD

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

UROCIT-K

		MISSION PHARMA	5MEQ	N19071	001	Aug 30, 1985	Jan	CTNA
	+		10MEQ	N19071	002	Aug 31, 1992	Jan	CTNA

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

	+	AMYLIN	EQ 3MG BASE/5ML (EQ 0.6MG BASE/ML)	N21332	001	Mar 16, 2005	Mar	NEWA

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA		IVAX PHARMS	15MG/5ML	N40287	001	May 28, 1999	Jan	CAHN
AA		TEVA PHARMS	15MG/5ML	N40322	001	Jan 19, 2000	Mar	CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

AA	+	UCB	EQ 5MG BASE/5ML	N19157	001	May 28, 1986	Mar	CAHN

PREDNISOLONE SODIUM PHOSPHATE

>A> AA		PHARM ASSOC	EQ 15MG BASE/5ML	N76913	001	Apr 25, 2005	Apr	NEWA

PRIMIDONE

TABLET; ORAL

MYSOLINE

>A>	AB	+ VALEANT	50MG	N09170	003		Apr	CAHN
>A>	AB		250MG	N09170	002		Apr	CAHN
>D>	AB	+ XCEL PHARMS	50MG	N09170	003		Apr	CAHN
>D>	AB		250MG	N09170	002		Apr	CAHN

PRIMIDONE

AB		VINTAGE PHARMS	50MG	N40586	001	Feb 24, 2005	Feb	NEWA
AB			250MG	N40586	002	Feb 24, 2005	Feb	NEWA

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

AB		TEVA PHARMS	EQ 5MG BASE	N40120	001	Jul 11, 1996	Mar	CAHN
AB			EQ 10MG BASE	N40120	002	Jul 11, 1996	Mar	CAHN

PROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

AO	+	WATSON LABS (UTAH)	50MG/ML	N17362	002		Feb	CAHN

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL
PROMETHAZINE HCL

		ABLE	12.5MG	N40558	001	Jul 01, 2004	Jan	CTEC

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL

	AB	BEDFORD	10MG/ML	N74848	001	Apr 19, 2005	Mar	NEWA

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
INDERAL

>D>	AB	+ WYETH PHARMS INC	10MG	N16418	001		Apr	CRLD
>A>	AB		10MG	N16418	001		Apr	CRLD

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HCL

	AB	EON	EQ 5MG BASE	N76803	001	Mar 02, 2005	Feb	NEWA
	AB		EQ 10MG BASE	N76803	002	Mar 02, 2005	Feb	NEWA
	AB		EQ 20MG BASE	N76803	003	Mar 02, 2005	Feb	NEWA
	AB		EQ 40MG BASE	N76803	004	Mar 02, 2005	Feb	NEWA
	AB	PAR PHARM	EQ 5MG BASE	N76036	001	Jan 28, 2005	Jan	NEWA
	AB		EQ 10MG BASE	N76036	002	Jan 28, 2005	Jan	NEWA
	AB		EQ 20MG BASE	N76036	003	Jan 28, 2005	Jan	NEWA
	AB		EQ 40MG BASE	N76036	004	Jan 28, 2005	Jan	NEWA

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE SULFATE

		+ TEVA PHARMS	300MG	N40045	001	Jun 30, 1994	Mar	CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
RANITIDINE HCL

	AP	BEN VENUE	EQ 25MG BASE/ML	N74777	001	Mar 02, 2005	Feb	NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)
AMMONUL

		+ UCYCLYD	10%;10% (5GM/50ML;5GM/50ML)	N20645	001	Feb 17, 2005	Feb	NEWA

SODIUM CHLORIDE

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	AT	HOSPIRA	450MG/100ML	N18380	001		Mar	CMFD

SOMATREM

INJECTABLE; INJECTION
PROTROPIN

		@ GENENTECH	5MG/VIAL	N19107	001	Oct 17, 1985	Mar	DISC
		@	10MG/VIAL	N19107	002	Oct 24, 1989	Mar	DISC

SOMATROPIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS
SEROSTIM LQ

	SERONO	6MG/0.05VIAL	N20604	005	Feb 11, 2005	Feb	NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	INTERPHARM	400MG;80MG	N76899	001	Jan 27, 2005	Jan	NEWA
AB		800MG;160MG	N76899	002	Jan 27, 2005	Jan	NEWA

TACROLIMUS

CAPSULE; ORAL
PROGRAF

+	FUJISAWA HLTHCARE	EQ 1MG BASE	N50708	001	Apr 08, 1994	Jan	CRLD

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

@	PHARMACHEMIE	EQ 10MG BASE	N74539	001	Mar 31, 2003	Feb	DISC

TELITHROMYCIN

TABLET; ORAL
KETEK

	AVENTIS PHARMS	300MG	N21144	002	Feb 09, 2005	Feb	NEWA

TERBUTALINE SULFATE

TABLET; ORAL
TERBUTALINE SULFATE

AB	LANNETT	2.5MG	N77152	001	Mar 25, 2005	Mar	NEWA
AB		5MG	N77152	002	Mar 25, 2005	Mar	NEWA

TERCONAZOLE

CREAM; VAGINAL
TERCONAZOLE

AB	ALTANA	0.4%	N76712	001	Feb 18, 2005	Jan	NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

AO	PADDOCK	200MG/ML	N40530	001	Jan 31, 2005	Jan	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
SUMYCIN

@	APOTHECON	250MG	N60429	001		Mar	DISC
@		500MG	N60429	003		Mar	DISC

TETRACYCLINE HCL

AB +	IVAX PHARMS	500MG	N60704	002		Mar	CRLD
@	MAST MM	250MG	N62085	001		Feb	DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOPHYLLINE

>D> BC	INWOOD LABS	125MG	N40052	002	Feb 14, 1994	Apr	CTEC

CAPSULE, EXTENDED RELEASE; ORAL
THEOPHYLLINE

>A>		INWOOD LABS	125MG	N40052	002	Feb 14, 1994	Apr	CTEC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

AA	+	TEVA PHARMS	30MG/ML	N89602	001	Nov 09, 1987	Mar	CAHN
AA	+		100MG/ML	N89603	001	Nov 09, 1987	Mar	CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

AA		TEVA PHARMS	EQ 5MG BASE/ML	N71554	001	Oct 16, 1987	Mar	CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
DETROL LA

>D>	+	PHARMACIA AND UPJOHN	2MG	N21228	001	Dec 22, 2000	Apr	CRLD
>A>			2MG	N21228	001	Dec 22, 2000	Apr	CRLD

TOREMIFENE CITRATE

TABLET; ORAL
FARESTON

	+	GTX INC	EQ 60MG BASE	N20497	001	May 29, 1997	Jan	CAHN

TORSEMIDE

TABLET; ORAL
TORSEMIDE

AB		ROXANE	5MG	N76943	001	Mar 01, 2005	Feb	NEWA
AB			10MG	N76943	002	Mar 01, 2005	Feb	NEWA
AB			20MG	N76943	003	Mar 01, 2005	Feb	NEWA

TRETINOIN

SOLUTION; TOPICAL
TRETINOIN

AT		TEVA PHARMS	0.05%	N74873	001	Jun 19, 1998	Mar	CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUA

		@ SCHERING	4MG	N12265	002		Feb	DISC

TRICHLORMETHIAZIDE

		@ ABC HOLDING	4MG	N85568	001		Feb	DISC
		@ PAR PHARM	2MG	N87007	001		Feb	DISC
		@	4MG	N87005	001		Feb	DISC

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL
PRIMSOL

	@	TARO PHARMS NORTH	EQ 25MG BASE/5ML	N74374	001	Jun 23, 1995	Jan	CAHN
	+		EQ 50MG BASE/5ML	N74973	001	Jan 24, 2000	Jan	CAHN

URSODIOL

CAPSULE; ORAL
URSODIOL

AB	TEVA PHARMS	300MG	N75592	001	May 25, 2000	Mar	CAHN

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID

AA	TEVA PHARMS	250MG/5ML	N73178	001	Aug 25, 1992	Mar	CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN PM

	ELAN PHARM	100MG	N20943	001	Nov 25, 1998	Mar	CRLD
		200MG	N20943	002	Nov 25, 1998	Mar	CRLD

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE

AP	AM PHARM	EQ 10MG BASE/ML	N76849	001	Apr 18, 2005	Mar	NEWA

ASPIRIN

TABLET; ORAL
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

		BAYER	500MG	N21317	001	Oct 18, 2001	Mar	CMFD

BENTOQUATAM

LOTION; TOPICAL
IVY BLOCK

>D>	+	ENVIRODERM	5%	N20532	001	Aug 26, 1996	Apr	CAHN
>A>	+	STAND HOMEOPATH	5%	N20532	001	Aug 26, 1996	Apr	CAHN

CHLORHEXIDINE GLUCONATE

CLOTH; TOPICAL
CHLORHEXIDINE GLUCONATE

>A>	+	SAGE PRODS	2%	N21669	001	Apr 25, 2005	Apr	NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

>D>		CHLORAPREP ONE-STEP FREPP						
>D>	+	MEDI FLEX HOSP	2%;70%	N20832	001	Jul 14, 2000	Apr	CTNA
>A>	+	MEDI FLEX INC	2%;70%	N20832	001	Jul 14, 2000	Apr	CTNA
>A>		CHLORAPREP WITH TINT						
>A>	+	MEDI FLEX INC	2%;70%	N20832	002	May 03, 2005	Apr	NEWA

CLOTRIMAZOLE

TABLET; VAGINAL
GYNIX

		TEVA PHARMS	100MG	N73249	001	Feb 13, 1998	Mar	CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
DELSYM

>D>	+	CELLTECH PHARMS	EQ 30MG HBR/5ML	N18658	001	Oct 08, 1982	Apr	CAHN
>A>	+	UCB	EQ 30MG HBR/5ML	N18658	001	Oct 08, 1982	Apr	CAHN

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE

		PERRIGO	10MG	N75400	001	Mar 18, 2005	Mar	NEWA
		WOCKHARDT	10MG	N77146	001	Mar 07, 2005	Feb	NEWA

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
IMODIUM A-D

>A>	+	MCNEIL	1MG/7.5ML	N19487	002	Jul 08, 2004	Apr	NEWA

LORATADINE

SYRUP; ORAL
CLARITIN HIVES RELIEF

		@ SCHERING	1MG/ML	N20641	003	Nov 19, 2003	Jan	DISC

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE 3

	TARO	4%	N76773	001	Mar 02, 2005	Feb	NEWA	

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

>D>	WATSON LABS	EQ 2MG BASE	N76568	001	Jul 29, 2004	Apr	DISC	
>A>	@	EQ 2MG BASE	N76568	001	Jul 29, 2004	Apr	DISC	
>D>		EQ 2MG BASE	N76569	001	Jul 29, 2004	Apr	CTNA	
>D>		EQ 4MG BASE	N76568	002	Jul 29, 2004	Apr	CTNA	
>D>		EQ 4MG BASE	N76569	002	Jul 29, 2004	Apr	DISC	
>A>	@	EQ 4MG BASE	N76569	002	Jul 29, 2004	Apr	DISC	

NICOTINE POLACRILEX (MINT)

>A>	WATSON LABS	EQ 2MG BASE	N76569	001	Jul 29, 2004	Apr	CTNA	
>A>		EQ 4MG BASE	N76568	002	Jul 29, 2004	Apr	CTNA	

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2005

NO APRIL 2005 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO APRIL 2005 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALBUTEROL SULFATE - ALBUTEROL SULFATE HFA								
021457 001		5605674	Feb 25, 2014		DP			
		5695743	Jul 06, 2010		DP	U-491		
	>A>	5766573	Nov 28, 2009			U-356		
		6352684	Nov 28, 2009		DP			
ALPRAZOLAM - NIRAVAM								
021726 001		6024981	Apr 09, 2018		DP			
		6221392	Apr 09, 2018		DP			
ALPRAZOLAM - NIRAVAM								
021726 002		6024981	Apr 09, 2018		DP			
		6221392	Apr 09, 2018		DP			
ALPRAZOLAM - NIRAVAM								
021726 003		6024981	Apr 09, 2018		DP			
		6221392	Apr 09, 2018		DP			
ALPRAZOLAM - NIRAVAM								
021726 004		6024981	Apr 09, 2018		DP			
		6221392	Apr 09, 2018		DP			
ARIPIPRAZOLE - ABILIFY								
021713 001							I-437	Sep 29, 2007
							I-401	Aug 28, 2006
							NCE	Nov 15, 2007
ARSENIC TRIOXIDE - TRISENOX								
021248 001		6855339	Nov 10, 2018			U-617		
		6861076	Nov 10, 2018			U-617		
ATOMOXETINE HYDROCHLORIDE - STRATTERA								
021411 007		5658590	Jan 11, 2015			U-494	NCE	Nov 26, 2007
	>A>	5658590*PED	Jul 11, 2015				PED	May 26, 2008
ATOMOXETINE HYDROCHLORIDE - STRATTERA								
021411 008		5658590	Jan 11, 2015			U-494	NCE	Nov 26, 2007
	>A>	5658590*PED	Jul 11, 2015				PED	May 26, 2008
BEXAROTENE - TARGRETIN								
021055 001	>A>	6043279	Apr 22, 2012			U-509		
	>A>	6320074	Apr 22, 2012	DS		U-509		
BEXAROTENE - TARGRETIN								
021056 001	>A>	6043279	Apr 22, 2012			U-510		
	>A>	6320074	Apr 22, 2012	DS		U-510		
BORTEZOMIB - VELCADE								
021602 001							I-452	Mar 25, 2008
BROMFENAC SODIUM - XIBROM								
021664 001							NP	Mar 24, 2008
BUDESONIDE - ENTOCORT EC								
021324 001							>A> I-454	Apr 29, 2008
CANDESARTAN CILEXETIL - ATACAND								
020838 001							I-448	Feb 22, 2008
CANDESARTAN CILEXETIL - ATACAND								
020838 002							I-448	Feb 22, 2008
CANDESARTAN CILEXETIL - ATACAND								
020838 003							I-448	Feb 22, 2008
CANDESARTAN CILEXETIL - ATACAND								
020838 004							I-448	Feb 22, 2008
CARBAMAZEPINE - CARBATROL								
020712 003	>A>	5326570	Jul 05, 2011			U-215		
	>A>	5912013	Jun 15, 2016			U-277		
CARBAMAZEPINE - EQUETRO								
021710 001		5326570	Jul 23, 2011		DP	U-627		
		5912013	Jun 15, 2016		DP			
CARBAMAZEPINE - EQUETRO								
021710 002		5326570	Jul 23, 2011		DP	U-627		
		5912013	Jun 15, 2016		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBAMAZEPINE - EQUETRO								
021710 003		5326570	Jul 23, 2011		DP	U-627		
		5912013	Jun 15, 2016		DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100								
021485 002	**>A>**	5446194	Oct 19, 2013	DS				
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150								
021485 003	**>A>**	5446194	Oct 19, 2013	DS				
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50								
021485 001	**>A>**	5446194	Oct 19, 2013	DS				
CETRORELIX - CETROTIDE								
021197 001		6863891	Feb 19, 2013			U-426		
CETRORELIX - CETROTIDE								
021197 002		6863891	Feb 19, 2013			U-426		
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
020832 002							**>A>** NP	May 03, 2008
CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC								
020805 001	**>A>**	4844902	Feb 11, 2008		DP			
	>A>	5843930	Jul 06, 2015			U-646		
CLOFARABINE - CLOLAR								
021673 001		4918179	Jun 14, 2005	DS				
		5384310	May 23, 2009	DS	DP			
		5661136	Aug 26, 2014			U-626		
COLESTIPOL HYDROCHLORIDE - COLESTID								
020222 001		5490987	Feb 13, 2013		DP			
DAPTOMYCIN - CUBICIN								
021572 001		6852689	Sep 24, 2019			U-282		
DAPTOMYCIN - CUBICIN								
021572 002		6852689	Sep 24, 2019			U-282		
DARIFENACIN HYDROBROMIDE - ENABLEX								
021513 001		5096890	Mar 13, 2010	DS	DP	U-631		
		6106864	Aug 21, 2016		DP	U-630		
DARIFENACIN HYDROBROMIDE - ENABLEX								
021513 002		5096890	Mar 13, 2010	DS	DP	U-631		
		6106864	Aug 21, 2016		DP	U-630		
DESIRUDIN RECOMBINANT - IPRIVASK								
021271 001							NCE	Apr 04, 2008
DESLORATADINE - CLARINEX								
021165 001	**>A>**	4659716	Apr 21, 2006			U-427		
	>A>	4659716*PED	Oct 21, 2006			U-427		
DESLORATADINE - CLARINEX								
021300 001	**>A>**	4659716	Apr 21, 2006		DP	U-611		
	>A>	4659716*PED	Oct 21, 2006					
DESLORATADINE - CLARINEX								
021312 001	**>A>**	4659716	Apr 21, 2006			U-427		
	>A>	4659716*PED	Oct 21, 2006			U-427		
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR								
021605 001	**>A>**	4659716	Apr 21, 2006		DP	U-644	NCE	Dec 21, 2006
	>A>	4659716*PED	Oct 21, 2006				NC	Mar 03, 2008
	>A>	6100274	Jul 07, 2019		DP		PED	Jun 21, 2007
	>A>	6100274*PED	Jan 07, 2020					
DEXRAZOXANE HYDROCHLORIDE - DEXRAZOXANE								
076068 001							PC	Aug 27, 2005
DEXRAZOXANE HYDROCHLORIDE - DEXRAZOXANE								
076068 002							**>A>** PC	Oct 19, 2005
DEXTROMETHORPHAN POLISTIREX - DELSYM								
018658 001	**>A>**	5980882	Apr 16, 2017		DP			
DIVALPROEX SODIUM - DEPAKOTE ER								
021168 001		6720004	Dec 18, 2018		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE	PATENT CODES			EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIVALPROEX SODIUM - DEPAKOTE ER								
021168 002		6720004	Dec 18, 2018		DP			
DOXAZOSIN MESYLATE - CARDURA XL								
021269 001							NDF	Feb 22, 2008
DOXAZOSIN MESYLATE - CARDURA XL								
021269 002		4837111	Mar 21, 2008		DP		NDF	Feb 22, 2008
ENTACAPONE - COMTAN								
020796 001	**>A>**	5446194	Oct 19, 2013	DS				
ENTECAVIR - BARACLUDE								
021797 001	**>A>**	5206244	Oct 18, 2010	DS			**>A>** NCE	Mar 29, 2010
ENTECAVIR - BARACLUDE								
021797 002	**>A>**	5206244	Oct 18, 2010	DS			**>A>** NCE	Mar 29, 2010
ENTECAVIR - BARACLUDE								
021798 001	**>A>**	5206244	Oct 18, 2010	DS			**>A>** NCE	Mar 29, 2010
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT								
021504 001		6862473	Sep 30, 2013		DP			
EPLERENONE - INSPRA								
021437 001		4559332	Apr 09, 2006	DS	DP	U-537		
EPLERENONE - INSPRA								
021437 002		4559332	Apr 09, 2006	DS	DP	U-537		
EPLERENONE - INSPRA								
021437 003		4559332	Apr 09, 2006	DS	DP	U-537		
ERTAPENEM SODIUM - INVANZ								
021337 001		5478820	Feb 02, 2013				NCE	Nov 21, 2006
		5478820*PED	Aug 02, 2013				PED	May 21, 2007
		5652233	Feb 02, 2013					
		5652233*PED	Aug 02, 2013					
		5952323	May 15, 2017					
		5952323*PED	Nov 15, 2017					
ESMOLOL HYDROCHLORIDE - ESMOLOL HCL								
076323 001							PC	May 01, 2005
ESOMEPRAZOLE MAGNESIUM - NEXIUM								
021153 001		4738974	Apr 19, 2006	DS	DP	U-635		
		4738974	Apr 19, 2006	DS	DP	U-373		
		4738974*PED	Oct 19, 2006			U-373		
		6875872	May 27, 2014	DS				
		6875872*PED	Nov 27, 2014					
ESOMEPRAZOLE MAGNESIUM - NEXIUM								
021153 002		4738974	Apr 19, 2006	DS	DP	U-635		
		4738974	Apr 19, 2006	DS	DP	U-373		
		4738974*PED	Oct 19, 2006			U-373		
		6875872	May 27, 2014	DS				
		6875872*PED	Nov 27, 2014					
ESOMEPRAZOLE SODIUM - NEXIUM IV								
021689 001	**>A>**	5877192	May 27, 2014			U-643	**>A>** NE	Mar 31, 2008
	>A>	5877192*PED	Nov 27, 2014				**>A>** NDF	Mar 31, 2008
	>A>	6143771	May 27, 2014		DP	U-643		
ESOMEPRAZOLE SODIUM - NEXIUM IV								
021689 002	**>A>**	5877192	May 27, 2014			U-643	**>A>** NE	Mar 31, 2008
	>A>	5877192*PED	Nov 27, 2014				**>A>** NDF	Mar 31, 2008
	>A>	6143771	May 27, 2014		DP	U-643		
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
021443 001		6660726	Mar 08, 2021	DS	DP	U-284	NP	Dec 20, 2007
		6660726	Mar 08, 2021	DS	DP	U-196		
		6855703	Feb 12, 2021	DS	DP	U-284		
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
021443 002		6660726	Mar 08, 2021	DS	DP	U-284	NP	Dec 20, 2007
		6660726	Mar 08, 2021	DS	DP	U-196		
		6855703	Feb 12, 2021	DS	DP	U-284		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA					
021443 003	6660726	Mar 08, 2021	DS DP U-284		
	6660726	Mar 08, 2021	DS DP U-196		
	6855703	Feb 12, 2021	DS DP U-284		
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA					
021443 004	6660726	Mar 08, 2021	DS DP U-284		
	6660726	Mar 08, 2021	DS DP U-196		
	6855703	Feb 12, 2021	DS DP U-284		
ESZOPICLONE - LUNESTA					
021476 001	6319926	Jan 16, 2012	U-620		
	6444673	Jan 16, 2012	DS DP		
	6864257	Aug 30, 2012	U-629		
ESZOPICLONE - LUNESTA					
021476 002	6319926	Jan 16, 2012	U-620		
	6444673	Jan 16, 2012	DS DP		
	6864257	Aug 30, 2012	U-629		
ESZOPICLONE - LUNESTA					
021476 003	6319926	Jan 16, 2012	U-620		
	6444673	Jan 16, 2012	DS DP		
	6864257	Aug 30, 2012	U-629		
EXENATIDE SYNTHETIC - BYETTA					
021773 001				**>A>** NCE	Apr 28, 2010
EXENATIDE SYNTHETIC - BYETTA					
021773 002				**>A>** NCE	Apr 28, 2010
FAMOTIDINE - FLUXID					
021712 001	6024981	Apr 09, 2018	DP		
	6221392	Apr 09, 2018	DP		
FAMOTIDINE - FLUXID					
021712 002	6024981	Apr 09, 2018	DP		
	6221392	Apr 09, 2018	DP		
FENTANYL - DURAGESIC-12					
019813 005				NPP	May 20, 2006
				PED	Nov 20, 2006
FENTANYL CITRATE - ACTIQ					
020747 001	5785989	May 01, 2005			
FENTANYL CITRATE - ACTIQ					
020747 002	5785989	May 01, 2005			
FENTANYL CITRATE - ACTIQ					
020747 003	5785989	May 01, 2005			
FENTANYL CITRATE - ACTIQ					
020747 004	5785989	May 01, 2005			
FENTANYL CITRATE - ACTIQ					
020747 005	5785989	May 01, 2005			
FENTANYL CITRATE - ACTIQ					
020747 006	5785989	May 01, 2005			
FLUOCINOLONE ACETONIDE - RETISERT					
021737 001				**>A>** NDF	Apr 08, 2008
FLUOCINONIDE - VANOS					
021758 001				NP	Feb 11, 2008
FLUTICASONE PROPIONATE - CUTIVATE					
021152 001				NDF	Mar 31, 2008
				PED	Sep 30, 2008
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50					
021077 001	6536427	Mar 01, 2011	DP		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50					
021077 002	6536427	Mar 01, 2011	DP		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50					
021077 003	6536427	Mar 01, 2011	DP		
GALANTAMINE HYDROBROMIDE - REMINYL					
021169 001	6358527	Jun 06, 2017	DP U-322		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GALANTAMINE HYDROBROMIDE - REMINYL							
021169 002		6358527	Jun 06, 2017	DP	U-322		
GALANTAMINE HYDROBROMIDE - REMINYL							
021169 003		6358527	Jun 06, 2017	DP	U-322		
GEMCITABINE HYDROCHLORIDE - GEMZAR							
020509 001		4808614	May 15, 2010	DS		I-428	May 19, 2007
		4808614*PED	Nov 15, 2010			>A> M-40	Apr 26, 2008
		5464826	Nov 07, 2012		U-146	>A> PED	Oct 26, 2008
		5464826*PED	May 07, 2013			PED	Nov 19, 2007
GEMCITABINE HYDROCHLORIDE - GEMZAR							
020509 002		4808614	May 15, 2010	DS		I-428	May 19, 2007
		4808614*PED	Nov 15, 2010			>A> M-40	Apr 26, 2008
		5464826	Nov 07, 2012		U-146	>A> PED	Oct 26, 2008
		5464826*PED	May 07, 2013			PED	Nov 19, 2007
GRANISETRON HYDROCHLORIDE - KYTRIL							
020239 003		4886808	Dec 29, 2007	DS	DP U-89	I-369	Aug 16, 2005
GRANISETRON HYDROCHLORIDE - KYTRIL							
020239 004						I-369	Aug 16, 2005
HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE							
020758 004	>A>	5270317	Sep 30, 2011	DS	DP		
	>A>	5270317*PED	Mar 30, 2012				
	>A>	5994348	Jun 07, 2015		DP		
	>A>	5994348*PED	Dec 07, 2015				
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR							
020387 001	>A>	5138069	Aug 11, 2009	DS			
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR							
020387 002	>A>	5138069	Aug 11, 2009	DS			
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT							
021532 002	>A>	6878703	Nov 19, 2021		U-3		
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT							
021532 003	>A>	6878703	Nov 19, 2021		U-3		
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT							
021532 005	>A>	6878703	Nov 19, 2021		U-3		
IBANDRONATE SODIUM - BONIVA							
021455 002	>A>	4927814	Jul 09, 2007	DS	DP U-642	D-96	Mar 24, 2008
	>A>	6294196	Oct 07, 2019		DP	NS	Mar 24, 2008
						NCE	May 16, 2008
IMATINIB MESYLATE - GLEEVEC							
021335 001		5521184	Jan 04, 2015				
IMATINIB MESYLATE - GLEEVEC							
021335 002		5521184	Jan 04, 2015				
IMATINIB MESYLATE - GLEEVEC							
021588 001		5521184	Jan 04, 2015				
IMATINIB MESYLATE - GLEEVEC							
021588 002		5521184	Jan 04, 2015				
ITRACONAZOLE - ITRACONAZOLE							
076104 001						PC	Aug 08, 2005
LETROZOLE - FEMARA							
020726 001						I-446	Oct 29, 2007
LEUPROLIDE ACETATE - ELIGARD							
021731 001		4938763	Oct 03, 2008		DP U-621		
		5278201	Jan 11, 2011		DP		
		5324519	Jun 28, 2011		DP		
		5599552	Feb 04, 2014		DP U-621		
		5739176	Oct 03, 2008		DP U-621		
		6395293	Sep 28, 2013		DP		
		6565874	Oct 28, 2018		DP U-621		
		6626870	Mar 27, 2020		DP		
		6773714	Oct 28, 2018		U-621		
		RE37950	Oct 03, 2008		DP U-621		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVALBUTEROL TARTRATE - XOPENEX HFA						
021730 001	**>A>** 5225183	Jul 06, 2010	DP		NP	Mar 11, 2008
	>A> 5362755	Nov 08, 2011		U-636		
	>A> 5439670	Jul 06, 2010	DP			
	>A> 5547994	Aug 20, 2013		U-636		
	>A> 5605674	Feb 25, 2014	DP			
	>A> 5695743	Jul 06, 2010	DP	U-636		
	>A> 5760090	Jan 05, 2010		U-636		
	>A> 5836299	Nov 17, 2017	DP			
	>A> 5844002	Jan 05, 2010		U-636		
	>A> 6083993	Jan 05, 2010		U-636		
	>A> 6352684	Nov 28, 2009	DP			
LINEZOLID - ZYVOX						
021130 001	5688792	Nov 18, 2014	DS	U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015			I-402	Jul 22, 2006
	6514529	Mar 15, 2021	DP		NPP	Dec 19, 2005
	6514529*PED	Sep 15, 2021			NCE	Apr 18, 2005
	6559305	Jan 29, 2021	DS		PED	Dec 23, 2007
	6559305*PED	Jul 29, 2021			PED	Jan 22, 2007
					PED	Jun 19, 2006
					PED	Oct 18, 2005
LINEZOLID - ZYVOX						
021130 002	5688792	Nov 18, 2014	DS	U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015			I-402	Jul 22, 2006
	6514529	Mar 15, 2021	DP		NPP	Dec 19, 2005
	6514529*PED	Sep 15, 2021			NCE	Apr 18, 2005
	6559305	Jan 29, 2021	DS		PED	Dec 23, 2007
	6559305*PED	Jul 29, 2021			PED	Jan 22, 2007
					PED	Jun 19, 2006
					PED	Oct 18, 2005
LINEZOLID - ZYVOX						
021131 001	5688792	Nov 18, 2014		U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015			I-402	Jul 22, 2006
	6559305	Jan 29, 2021	DS		NPP	Dec 19, 2005
	6559305*PED	Jul 29, 2021			NCE	Apr 18, 2005
					PED	Dec 23, 2007
					PED	Jan 22, 2007
					PED	Jun 19, 2006
					PED	Oct 18, 2005
LINEZOLID - ZYVOX						
021132 001	5688792	Nov 18, 2014	DS	U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015			I-402	Jul 22, 2006
	6559305	Jan 29, 2021	DS		NPP	Dec 19, 2005
	6559305*PED	Jul 29, 2021			NCE	Apr 18, 2005
					PED	Dec 23, 2007
					PED	Jan 22, 2007
					PED	Jun 19, 2006
					PED	Oct 18, 2005
LOVASTATIN - ALTOPREV						
021316 001	6485748	Dec 12, 2017	DP			
LOVASTATIN - ALTOPREV						
021316 002	6485748	Dec 12, 2017	DP			
LOVASTATIN - ALTOPREV						
021316 003	6485748	Dec 12, 2017	DP			
LOVASTATIN - ALTOPREV						
021316 004	6485748	Dec 12, 2017	DP			
MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104						
021583 001	6495534	May 15, 2020	DP		I-451	Mar 25, 2008
MELOXICAM - MOBIC						
020938 001					I-430	Jul 16, 2007
					NCE	Apr 13, 2005
					PED	Jan 16, 2008
					PED	Oct 13, 2005

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MELOXICAM - MOBIC					
021530 001	6184220	Mar 25, 2019	DP	I-430	Jul 16, 2007
	6184220*PED	Sep 25, 2019		NCE	Apr 13, 2005
				PED	Jan 16, 2008
				PED	Oct 13, 2005
METFORMIN HYDROCHLORIDE - FORTAMET					
021574 001	6866866	Mar 17, 2021	DP		
METFORMIN HYDROCHLORIDE - FORTAMET					
021574 002	6866866	Mar 17, 2021	DP		
METFORMIN HYDROCHLORIDE - METFORMIN HCL					
076863 001				PC	Apr 12, 2005
METOPROLOL SUCCINATE - TOPROL-XL					
019962 001	4927640	May 22, 2007	DP	D-95	Feb 15, 2008
	4957745	Sep 18, 2007	DP U-107		
	5001161	Sep 18, 2007	DP		
	5081154	Sep 18, 2007	DS		
METOPROLOL SUCCINATE - TOPROL-XL					
019962 002	4927640	May 22, 2007	DP	D-95	Feb 15, 2008
	4957745	Sep 18, 2007	DP U-107		
	5001161	Sep 18, 2007	DP		
	5081154	Sep 18, 2007	DS		
METOPROLOL SUCCINATE - TOPROL-XL					
019962 003	4927640	May 22, 2007	DP	D-95	Feb 15, 2008
	4957745	Sep 18, 2007	DP U-107		
	5001161	Sep 18, 2007	DP		
	5081154	Sep 18, 2007	DS		
METOPROLOL SUCCINATE - TOPROL-XL					
019962 004	4927640	May 22, 2007	DP	D-95	Feb 15, 2008
	4957745	Sep 18, 2007	DP U-107		
	5001161	Sep 18, 2007	DP U-107		
	5081154	Sep 18, 2007	DS U-107		
MICAFUNGIN SODIUM - MYCAMINE					
021506 002				NCE	Mar 16, 2010
MODAFINIL - PROVIGIL					
020717 001				I-449	Jan 23, 2007
MODAFINIL - PROVIGIL					
020717 002				I-449	Jan 23, 2007
MOMETASONE FUROATE - ASMANEX TWISTHALER					
021067 001	**>A>** 5394868	Jun 25, 2012	DP	NP	Mar 30, 2008
	>A> 5687710	Nov 18, 2014	DP		
	>A> 5829434	Nov 03, 2015	DP		
	>A> 5889015	Jan 27, 2014	U-645		
	>A> 6057307	Jan 27, 2014	DP U-645		
	>A> 6240918	Feb 20, 2017	DP		
	>A> 6365581	Jan 27, 2014	U-645		
	>A> 6503537	Mar 17, 2018	DP		
	>A> 6677322	Jan 27, 2014	U-645		
MOMETASONE FUROATE MONOHYDRATE - NASONEX					
020762 001	5837699	Jan 27, 2014	DP U-625		
	6127353	Oct 03, 2017	DS DP		
	6723713	Jan 27, 2014	U-625		
NATEGLINIDE - STARLIX					
021204 001	6844008	Nov 14, 2017	DP U-214		
	RE34878	Sep 08, 2009			
NATEGLINIDE - STARLIX					
021204 002	6844008	Nov 14, 2017	DP U-214		
	RE34878	Sep 08, 2009			
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
076313 001				**>A>** PC	Oct 02, 2005
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
076313 002				**>A>** PC	Oct 02, 2005

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE			PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)									
076313 003								>A> PC	Oct 02, 2005
OCTREOTIDE ACETATE - SANDOSTATIN									
019667 005		5753618	Jul	08,	2008				
OLMESARTAN MEDOXOMIL - BENICAR									
021286 001	>A>	6878703	Nov	19,	2021		U-3		
OLMESARTAN MEDOXOMIL - BENICAR									
021286 003	>A>	6878703	Nov	19,	2021		U-3		
OLMESARTAN MEDOXOMIL - BENICAR									
021286 004	>A>	6878703	Nov	19,	2021		U-3		
OMEPRAZOLE - ZEGERID									
021706 001		5840737	Jul	16,	2016	DS	U-624		
		5840737	Jul	16,	2016	DS	U-623		
		6489346	Jul	16,	2016	DS DP	U-624		
		6489346	Jul	16,	2016	DS DP	U-623		
		6645988	Jul	16,	2016	DS DP			
		6699885	Jul	16,	2016		U-624		
		6699885	Jul	16,	2016		U-623		
		6780882	Jul	16,	2016	DS DP			
ONDANSETRON HYDROCHLORIDE - ZOFRAN									
020007 001								>A> D-98	Mar 25, 2008
								D-97	Mar 25, 2008
								>A> PED	Sep 25, 2008
								PED	Sep 25, 2008
ONDANSETRON HYDROCHLORIDE - ZOFRAN PRESERVATIVE FREE									
020007 003								>A> D-98	Mar 25, 2008
								D-97	Mar 25, 2008
								>A> PED	Sep 25, 2008
								PED	Sep 25, 2008
OXALIPLATIN - ELOXATIN									
021759 001								I-441	Nov 04, 2007
								NCE	Aug 09, 2007
OXALIPLATIN - ELOXATIN									
021759 002								I-441	Nov 04, 2007
								NCE	Aug 09, 2007
OXCARBAZEPINE - TRILEPTAL									
021014 001								NCE	Jan 14, 2005
								PED	Jul 14, 2005
OXCARBAZEPINE - TRILEPTAL									
021014 002								NCE	Jan 14, 2005
								PED	Jul 14, 2005
OXCARBAZEPINE - TRILEPTAL									
021014 003								NCE	Jan 14, 2005
								PED	Jul 14, 2005
OXCARBAZEPINE - TRILEPTAL									
021285 001								NCE	Jan 14, 2005
								PED	Jul 14, 2005
PACLITAXEL - ABRAXANE									
021660 001		5439686	Feb	22,	2013	DP		NP	Jan 07, 2008
		5498421	Mar	12,	2013	DP	U-634		
		6096331	Feb	22,	2013	DP	U-633		
		6506405	Feb	22,	2013	DP	U-633		
		6537579	Feb	22,	2013		U-632		
		6749868	Feb	22,	2013	DP			
		6753006	Feb	22,	2013	DP			
PEGAPTANIB SODIUM - MACUGEN									
021756 001		5919455	Oct	27,	2013	DS			
		5932462	Aug	03,	2016	DS			
		6011020	Jan	04,	2017	DS			
		6051698	Sep	17,	2012	DS			
		6113906	Oct	27,	2013	DS			
		6147204	Jun	11,	2010	DS			
		6426335	Jun	11,	2010		U-622		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE			PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PRAMLINTIDE ACETATE - SYMLIN									
021332 001	**>A>**	5175145	Dec 29, 2009				U-637	NCE	Mar 16, 2010
	>A>	5686411	Nov 11, 2014	DS	DP		U-638		
	>A>	5814600	Sep 29, 2015				U-639		
	>A>	5998367	Mar 08, 2011	DS	DP				
	>A>	6114304	Sep 05, 2017				U-640		
	>A>	6410511	Jan 09, 2018		DP				
	>A>	6608029	Sep 07, 2013				U-641		
	>A>	6610824	Mar 08, 2011	DS					
PREGABALIN - LYRICA									
021446 001		6001876	Jul 16, 2017				U-55		
		6197819	Mar 06, 2018	DS	DP				
PREGABALIN - LYRICA									
021446 002		6001876	Jul 16, 2017				U-55		
		6197819	Mar 06, 2018	DS	DP				
PREGABALIN - LYRICA									
021446 003		6001876	Jul 16, 2017				U-55		
		6197819	Mar 06, 2018	DS	DP				
PREGABALIN - LYRICA									
021446 004		6001876	Jul 16, 2017				U-55		
		6197819	Mar 06, 2018	DS	DP				
PREGABALIN - LYRICA									
021446 005		6001876	Jul 16, 2017				U-55		
		6197819	Mar 06, 2018	DS	DP				
PREGABALIN - LYRICA									
021446 006		6001876	Jul 16, 2017				U-55		
		6197819	Mar 06, 2018	DS	DP				
PREGABALIN - LYRICA									
021446 007		6001876	Jul 16, 2017				U-55		
		6197819	Mar 06, 2018	DS	DP				
PREGABALIN - LYRICA									
021446 008		6001876	Jul 16, 2017				U-55		
		6197819	Mar 06, 2018	DS	DP				
RIBAVIRIN - COPEGUS									
021511 001								I-447	Feb 25, 2008
RISPERIDONE - RISPERDAL									
021444 004	**>A>**	4804663	Dec 29, 2007	DS	DP		U-543		
	>A>	5648093	Jul 15, 2014		DP				
	>A>	6224905	Jun 10, 2017		DP				
RISPERIDONE - RISPERDAL									
021444 005	**>A>**	4804663	Dec 29, 2007	DS	DP		U-543		
	>A>	5648093	Jul 15, 2014		DP				
	>A>	6224905	Jun 10, 2017		DP				
ROSIGLITAZONE MALEATE - AVANDIA									
021071 002		5002953	Aug 30, 2008	DS	DP		U-628	I-453	Feb 28, 2008
		5002953	Aug 30, 2008	DS	DP		U-329		
		5741803	Apr 21, 2015	DS	DP		U-628		
		5741803	Apr 21, 2015	DS	DP		U-329		
ROSIGLITAZONE MALEATE - AVANDIA									
021071 003		5002953	Aug 30, 2008	DS	DP		U-628	I-453	Feb 28, 2008
		5002953	Aug 30, 2008	DS	DP		U-329		
		5741803	Apr 21, 2015	DS	DP		U-628		
		5741803	Apr 21, 2015	DS	DP		U-329		
ROSIGLITAZONE MALEATE - AVANDIA									
021071 004		5002953	Aug 30, 2008	DS	DP		U-628	I-453	Feb 28, 2008
		5002953	Aug 30, 2008	DS	DP		U-329		
		5741803	Apr 21, 2015	DS	DP		U-628		
		5741803	Apr 21, 2015	DS	DP		U-329		
ROSUVASTATIN CALCIUM - CRESTOR									
021366 002		6858618	Dec 17, 2021				U-618		
ROSUVASTATIN CALCIUM - CRESTOR									
021366 003		6858618	Dec 17, 2021				U-618		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROSUVASTATIN CALCIUM - CRESTOR								
021366 004		6858618	Dec 17, 2021			U-618		
ROSUVASTATIN CALCIUM - CRESTOR								
021366 005		6858618	Dec 17, 2021			U-618		
SIROLIMUS - RAPAMUNE								
021083 001	>A>	5536729	Sep 30, 2013		DP		>A> NPP	Mar 11, 2008
							>A> PED	Sep 11, 2008
SIROLIMUS - RAPAMUNE								
021110 001	>A>	5989591	Mar 11, 2018		DP		>A> NPP	Mar 11, 2008
							>A> PED	Sep 11, 2008
SIROLIMUS - RAPAMUNE								
021110 002	>A>	5989591	Mar 11, 2018		DP		>A> NPP	Mar 11, 2008
							>A> PED	Sep 11, 2008
SIROLIMUS - RAPAMUNE								
021110 003	>A>	5100899	Jun 06, 2009			U-290	>A> NPP	Mar 11, 2008
	>A>	5100899*PED	Dec 06, 2009				>A> PED	Sep 11, 2008
	>A>	5212155	May 18, 2010			U-291		
	>A>	5212155*PED	Nov 18, 2010					
	>A>	5403833	Apr 04, 2012			U-293		
	>A>	5403833*PED	Oct 04, 2012					
	>A>	5989591	Mar 11, 2018		DP			
	>A>	5989591*PED	Sep 11, 2018					
SODIUM BENZOATE; SODIUM PHENYLACETATE - AMMONUL								
020645 001							NDF	Feb 17, 2008
							ODE	Feb 17, 2012
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE								
020280 001	>A>	4968299	Jun 28, 2008		DP			
		6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE								
020280 002	>A>	4968299	Jun 28, 2008		DP			
		6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE								
020280 003	>A>	4968299	Jun 28, 2008		DP			
		6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE								
020280 005	>A>	4968299	Jun 28, 2008		DP			
		6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE								
020280 008	>A>	4968299	Jun 28, 2008		DP			
		6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE								
020280 009	>A>	4968299	Jun 28, 2008		DP			
		6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE								
020280 010	>A>	4968299	Jun 28, 2008		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE								
020280 011	>A>	4968299	Jun 28, 2008		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE								
020280 012	>A>	4968299	Jun 28, 2008		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE								
020280 013	>A>	4968299	Jun 28, 2008		DP			
TELITHROMYCIN - KETEK								
021144 002	>A>	5635485	Apr 21, 2015	DS	DP	U-578	NCE	Apr 01, 2009
	>A>	D459798	Sep 24, 2015		DP			
TEMOZOLOMIDE - TEMODAR								
021029 001		5260291	Aug 11, 2013	DS	DP	U-619	I-450	Mar 15, 2008
		5260291*PED	Feb 11, 2014				ODE	Mar 15, 2012
TEMOZOLOMIDE - TEMODAR								
021029 002		5260291	Aug 11, 2013	DS	DP	U-619	I-450	Mar 15, 2008
		5260291*PED	Feb 11, 2014				ODE	Mar 15, 2012

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TEMOZOLOMIDE - TEMODAR					
021029 003	5260291	Aug 11, 2013	DS DP U-619	I-450	Mar 15, 2008
	5260291*PED	Feb 11, 2014		ODE	Mar 15, 2012
TEMOZOLOMIDE - TEMODAR					
021029 004	5260291	Aug 11, 2013	DS DP U-619	I-450	Mar 15, 2008
	5260291*PED	Feb 11, 2014		ODE	Mar 15, 2012
THALIDOMIDE - THALOMID					
020785 001	**>A>** 6869399	Oct 23, 2020	U-371		
THALIDOMIDE - THALOMID					
020785 002	**>A>** 6869399	Oct 23, 2020	U-371		
THALIDOMIDE - THALOMID					
020785 003	**>A>** 6869399	Oct 23, 2020	U-371		
TOPIRAMATE - TOPAMAX					
020505 001				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX					
020505 002				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX					
020505 003				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX					
020505 004				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX					
020505 005				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX					
020505 006				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX SPRINKLE					
020844 001				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX SPRINKLE					
020844 002				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX SPRINKLE					
020844 003				I-41	Aug 11, 2007
VORICONAZOLE - VFEND					
021266 001	5567817	May 24, 2016	DS DP U-540		
VORICONAZOLE - VFEND					
021266 002	5567817	May 24, 2016	DS DP U-540		
VORICONAZOLE - VFEND					
021267 001	5567817	May 24, 2016	DS DP U-540		
VORICONAZOLE - VFEND					
021630 001	5567817	May 24, 2016	DS DP U-540		
ZICONOTIDE - PRIALT					
021060 001	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		
ZICONOTIDE - PRIALT					
021060 002	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		
ZICONOTIDE - PRIALT					
021060 003	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZICONOTIDE - PRIALT					
021060 004	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:

DS = Drug Substance claim

DP = Drug Product claim

U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm

3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of Patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm